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Abstract 
Calmodulin (CaM) is a small, highly conserved and ubiquitous calcium (Ca2+)-sensing 
protein that coordinates signal transduction through interactions with over 300 target molecules. 
It is composed of N- and C-terminal globular domains separated by a central flexible linker 
region. Each domain contains two EF hands that each coordinate one Ca2+. CaM exists primarily 
as either Ca2+-deplete apo-CaM or Ca2+-saturated holo-CaM. Ca2+ binding causes a 
conformational change that exposes hydrophobic regions within each domain which facilitates 
binding to various targets, although apo-CaM is also able to bind to certain molecular targets as 
well.  
An important set of targets for CaM are the nitric oxide synthase (NOS) isozymes. NOS 
catalyzes the conversion of L-arginine to L-citrulline in the production of nitric oxide (•NO). 
There are three isoforms of mammalian NOS: neuronal NOS (nNOS), endothelial NOS (eNOS) 
and inducible (iNOS). All three isoforms possess an N-terminal oxygenase domain containing 
the active site and a C-terminal reductase domain containing binding sites for FAD, FMN and 
NADPH. CaM binds to a region situated between these two domains, enabling interdomain 
electron transfer via a highly dynamic process. Ca2+-dependent nNOS and eNOS isoforms are 
expressed constitutively, whereas Ca2+-independent iNOS is regulated transcriptionally and 
expressed transiently. NOS isozymes perform various biologically important functions yet 
represent important therapeutic targets for inhibition in certain cases of overexpression. In one 
such instance, the overexpression of nNOS and subsequent overproduction of •NO in the central 
nervous system have been implicated in the pathogenesis of many neurodegenerative conditions 
including ischemic brain injury and epilepsy.  
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One approach that has yielded success in the selective inhibition of nNOS is the use of 
CaM antagonists such as trifluoperazine (TFP). TFP is available commercially as an 
antipsychotic medication and is used to treat symptoms of schizophrenia. The strong nature of its 
antagonism towards CaM corresponds to high levels of cytotoxicity as TFP has been shown to 
negatively impact various cellular processes. There is some evidence suggesting that melatonin 
(aMT) and one of its metabolites, N1-acetyl-5-methoxykynuramine (AMK), act as CaM 
antagonists and are able to appreciably inhibit nNOS activity. These naturally occurring 
hormones could prove to be milder and less cytotoxic alternatives to TFP, yet their mechanism of 
action remains poorly understood. A structural understanding of how these compounds interact 
with CaM and nNOS are important in further elucidating their value as therapeutic agents.  
We sought to evaluate the nature of these interactions, with a particular focus on AMK, 
using numerous biophysical techniques at saturating levels of Ca2+. Far-UV CD, gel mobility 
assays and ITC experiments demonstrated that the association of aMT and AMK with CaM is 
very weak, as had been seen in previous studies with aMT alone. CD and SPR competition 
assays showed a subtle AMK-mediated selective reduction in complex formation between CaM 
and the CaM-binding domain peptide of nNOS. NMR solution structures of CaM bound to AMK 
revealed that the ligand does not cause significant conformational changes in the protein, with 
the globular domains retaining their orientational independence from one another. The strengths 
of residue-specific interactions with AMK were determined to be in the low millimolar range 
using 15N-HSQC NMR titrations, with N- and C-terminal domains possessing comparable 
affinities. Likely binding surfaces were determined to be located primarily in the hydrophobic 
cavities within each domain. This was corroborated by molecular dynamics studies, in which the 
most stable binding modes occurred when AMK was localized hydrophobic patches in the N-
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terminal domain. We propose that the inhibitory effects of AMK are likely the result of a 
modulation of cellular function via gentle antagonism of CaM. The low affinity of CaM-AMK 
complexation would suggest allosteric alteration of the CaM-nNOS complex rather than direct 
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Chapter 1 
 Literature Review 
 
1.1 Calcium Signalling Pathway 
 Calcium (Ca2+) is an ion used in cellular signalling, exerting allosteric regulation on 
numerous enzymes and proteins. Intracellular Ca2+ regulation is involved in processes such as 
muscle contraction, neuronal transmission, fertilization, cell motility and growth, neurogenesis 
and synaptic plasticity.1,2 Basal concentration ranges from 50-100 nM, and increases by up to 
100 fold during certain cellular functions.3 These processes are facilitated by Ca2+-sensing 
proteins, which often contain a structural element known as an EF hand. An EF hand is a helix-
loop-helix structural motif in which Ca2+ is coordinated by ligands in the loop domain (Figure 
1.1A). The presence of oxygen is critical to protein binding to Ca2+ within these domains, as 
negatively charged oxygen from glutamate and aspartate sidechains have high affinity for Ca2+.4  
EF hands are typically found in pairs with adjacent loop domains associating through antiparallel 
β-sheet hydrogen bonds. The amphipathic helices conform with hydrophobic regions being 
packed inwards into a tight core, consolidated by inter- and intrahelical hydrophobic interactions. 
Conversely, the outward facing solvent-exposed regions contain charged residues that interact 
with ions and solvent through favourable electrostatic interactions.5  One prominent Ca2+-binding 
protein is Calmodulin (CaM), whose EF hand loop domains are 12 amino acids in length and 
rich in aspartate residues, which are important in the pentagonal bipyramidal coordination of 
Ca2+ via 7 oxygen containing-ligands in residues 1-3-5-7-9-12 (Figure 1.1B). The coil structure 






1.2 Calmodulin Overview 
  CaM is a homologous, multifunctional messenger protein consisting of 148 amino acids 
and weighing 16700 Da. It is targeted and successively activated by Ca2+, whereupon CaM 
coordinates Ca2+ signal transduction cascades through interactions with various target proteins 
and enzymes.6,7 Many of these target proteins cannot bind to Ca2+ independently and thus require 
CaM for activation. CaM is always expressed intracellularly but is also expressed in a range of 
cell types and organelles. It has been found in all eukaryotic organisms and is involved in 
numerous cellular processes including division, fertilization, secretion, contraction and motility 
and neurotransmission.8 
 The ubiquity of CaM implicates it in mediating many crucial physiological functions 
including facilitating smooth muscle contraction. This is accomplished by initiating cross-bridge 




Figure 1.1 EF hand structure and Ca2+ coordination. 
(A) The helix-loop-helix structural motif of the first EF hand in CaM. (B) The coordination of 
Ca2+ in the first EF hand. Dark red corresponds to CaM, green to Ca2+, beige to amino acid 
sidechains and bright red to oxygen. Contacts are represented by a purple dashed line. 









phosphorylation, MLC kinase, is Ca2+-dependent and is activated by the binding of CaM.10 CaM 
has also been shown play a role in memory and long-term potentiation (LTP). Ca2+/CaM-
dependent protein kinase II (CaMKII) is central to Ca2+ and cyclic adenosine monophosphate 
(cAMP) signalling for long-term memory formation.11,12 CaM is also involved in metabolism via 
the activation of phosphorylase kinase and through actuating calcitonin. Calcitonin regulates 
blood Ca2+ levels as well as G protein-induced cAMP production and CaM inhibition has been 
found to decrease these regulatory effects.13 
 
1.2.1 CaM Structure 
 CaM is a small, highly acidic protein possessing N- and C-terminal globular domains that 
share 75% sequence homology, connected by a central flexible linker region. The N-terminal 
domain is located from residues 1-75, the linker region from 76-81, and the C-terminal domain 
from 82-148. Both domains contain two EF hand motifs that each bind to a single Ca2+ ion, 
meaning that CaM has the ability to bind up to four Ca2+ ions in total.14 The Ca2+-binding loop 
segments of the EF hands are located in amino acid residues 21-31, 57-68, 94-105 and 130-141 
in CaM. Constitutive differences between domains confer each with distinct electrostatic 
potential surfaces, resulting in asymmetric Ca2+ affinity. The more rigid C-terminal EF hands 
have a 10-fold higher affinity (Kd = 10-6 M) in comparison to EF hands localized to the more 
flexible N-terminal (Kd = 10-5  M).14 Ca2+ binds sequentially to EF hands III, IV, I and II and 
dissociates in reverse order.15 Ca2+-CaM complexes exist primarily in one of two states: Ca2+-
deplete apo-CaM (Figure 1.2A) and fully Ca2+-replete holo-CaM (Figure 1.2B).  
 Ca2+ binding to CaM induces several conformational changes in helix packing that 
promote binding to target proteins. Apo-CaM adopts a shorter, more compact structure with α-
 4 
helices of the two proximal EF hands aligning in an antiparallel fashion with interhelical angles 
of 128°-137°. Conversely, in holo-CaM the EF-hand helices open with interhelical angles in a 
near perpendicular orientation (86°-101°). This change permits negatively charged sidechains to 
coordinate the Ca2+ ion, exposing hydrophobic cavities in each domain involved in protein 
recognition that are closed in apo-CaM.16 These exposed hydrophobic regions are rich in 
methionine residues, with 4 per domain and 1 in the central linker region. The 9 methionine 
residues constitute 46% of the hydrophobic surface area within the cavities and are considered to 
be responsible for target recognition due to the flexible sidechains and polarizable sulphur 
atoms.17 In contrast, apo-CaM surfaces are predominantly hydrophilic, lacking the exposed 
hydrophobic domains necessary to capture the aliphatic and aromatic sidechains of the target 
binding proteins.16 Although more compact, apo-CaM is more dynamic, with Ca2+-binding 





Figure 1.2 Structures of CaM and the eNOS CaM-binding region in complex with holo-
CaM. 
The crystal structure of (A) apo-CaM, (B) holo-CaM and (C) holo-CaM in complex with the 
eNOS CaM-binding domain. CaM is shown in red, the CaM binding peptide is shown in blue 
and Ca2+ is depicted as a green sphere. Models were derived from PBD 1CFD, 1CLN, and 
2LL7 respectively and visualized using USCF Chimera v. 1.13.1. 
 
A B C 
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1.2.2 CaM Binding to Target Proteins 
 CaM is able to bind to basic, amphiphilic α-helices within a large number of target 
proteins. This promiscuity does not translate to non-specific interaction, as the flexible central 
linker region between the two globular domains allows CaM to adopt a wide variety of 
conformations and bind with high affinity and selectivity.18 This process generally involves 
wrapping the N- and C- terminal domains around the target protein (Figure 1.2C). The alignment 
of the CaM C-terminal towards the C-terminal of the protein (same with respect to N-terminals) 
is categorized as a parallel conformation; antiparallel consists of the N- and C-terminals of CaM 














Target proteins that bind to CaM generally possess a binding domain of approximately 20 
amino acids. Some examples of well characterized CaM binding proteins from other studies are 
shown in Table 1.1.20–22 Apo-CaM primarily adopts the consensus IQ binding motif with the 
general form IQXXXRGXXXR, where X represents any amino acid. Holo-CaM binding 
Group Target enzyme of protein Number of Ca2+ 
CaM Binding with Canonical Binding mode 
Protein Kinases CaM-dependent protein kinase I (CAMKI) 4 
CaM-dependent protein kinase II (CAMKII) 4 
Myosin light chain kinase (MLCK) 4 
Death-associated protein kinase (DAPK) 4 
Phosphatases Calcineurin 4 
Secondary Messengers Nitric Oxide Synthase (NOS) 4 
Inducible NOS 0 
Plasma-membrane Ca2+-ATPases (PMCA)  4 
Voltage-dependent Ca2+ channels (CaV1.1)  4 
Voltage-dependent Ca2+ channels (CaV1.1)  4 
Ryanodine receptor RYR1  4 





CaM Binding in Elongated Binding Mode 
Ion Channels Bacillus anthracis edema factor (EF) 2 
Small-conductance Ca2+-activated K+ 
channels (SK2)  
2 
Voltage-gated sodium channels (Nav1.5)  4 
Nav1.5  0 
Table 1.1 Overview of some CaM-target proteins 
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domains predominantly follows a 1-5-10 or 1-5-8-14 motif, each named after positions of 
conserved residues within their respective motifs with the outer numbers denoting anchoring 
residues. These anchoring residues bind to hydrophobic patches containing methionine 
sidechains in the terminal domains of CaM, facilitating interactions between the linker region 
and the basic residues in between the anchors.23 Binding orientation is mediated by the glutamic 
acid residues forming rings around these methionine pockets. Specificity is further achieved 
through the formation of hydrogen bonds and salt bridges between polar sidechains in the central 
linker and the binding domain, as well as between the N- and C-terminal domains of CaM and 
basic residues in the target sequence.18,24 These residues are abundant in nitric oxide synthase 
(NOS) isozymes; the CaM-binding domain of neuronal NOS (nNOS) is highly basic and has 
only one acidic residue.25 Due to this basicity, nNOS is able to interact electrostatically with 
glutamate residues in both domains of CaM.24 Interactions between CaM and NOS have been 
widely studied, as mammalian NOS isoforms are involved in numerous essential biological 
functions. 
 
1.3 Nitric Oxide Synthase  
 NOS is a catalytic enzyme responsible for the conversion of L-arginine to L-citrulline 
and nitric oxide (•NO) via a series of mono-oxygenase reactions. NOS uses nicotinamide-
adenine-dinucleotide phosphate (NADPH) as a co-substrate, donating hydride ions in the 
presence of molecular oxygen. Flavin adenine dinucleotide (FAD), flavin mononucleotide 




1.3.1 NOS Isoforms 
 •NO synthesis has been observed in most organisms, ranging from animal cells to fungi, 
bacteria and plants. Mammalian NOS is present in vivo in three isoforms: neuronal NOS (nNOS, 
NOS I), inducible NOS (iNOS, NOS II) and endothelial NOS (eNOS, NOS III). iNOS is 
expressed transiently, whereas eNOS and nNOS are expressed constitutively, and are therefore 
collectively known as constitutive NOS (cNOS). All isoforms require CaM binding for 
enzymatic activity; cNOS is Ca2+ dependent whereas iNOS is regulated at the transcriptional 
level and is Ca2+ independent. Additionally, cNOS activation is contingent on the binding of both 
N- and C-lobes of CaM, where iNOS only requires the N-lobe.28 These isoforms have a 51-57% 
sequence homology and vary in size with eNOS, nNOS and iNOS having molecular weights of 
133, 165 and 130 kDa, respectively 27,29 The expression of nNOS is primarily localized in central 
and peripheral neuronal tissue. It functions as a retrograde neurotransmitter and regulates 
synaptic plasticity in the central nervous system (CNS).30 iNOS synthesizes large quantities of 
•NO in a variety of cell types as an immune response to cytokines and has a cytostatic effect on 
invasive parasites, tumours and bacterial growth.31 eNOS is localized predominantly to 




endothelial cells. It is involved in several vascular functions including insulin secretion, 
angiogenesis and regulation of vascular tone.32 All NOS isoforms possess a bidomain structure, 
consisting of an N-terminal oxygenase domain and a C-terminal reductase domain. Within the 
oxygenase domain are binding sites for H4B, heme, L-arginine and molecular oxygen.27 The 
reductase domain is connected to the oxygenase domain by a central CaM-binding region and 






 The NOS catalytic mechanism is predicated upon the concept of interdomain electron 
transfer (IET), wherein electrons pass from NADPH to FAD, then FMN and finally to the heme 
complex. CaM is necessary for this process, acting as a molecular switch to fully activate the 
enzyme upon binding. The CaM-binding domain sequence of human NOS consists of residues 
731-752 for nNOS, 501-531 for iNOS, and 491-512 for eNOS.33,34 Both nNOS and eNOS follow 
the characteristic holo-CaM-peptide 1-5-8-14 binding motif, however iNOS does not follow 
consensus apo-CaM IQ binding. Instead, iNOS also contains the 1-5-8-14 binding motif and 
Figure 1.4 Domain structure of NOS isozymes. 
The oxygenase domain is shown in blue with the nNOS PDZ domain shown in light blue. The 
reductase domain is displayed with the FMN and FAD/NADPH subdomains shown in green 
and yellow respectively. The autoinhibitory regions of eNOS and nNOS are shown in purple. 
The oxygenase domain and reductase domains are separated by a CaM-binding region shown in 
red. 
 
Oxygenase Domain Reductase Domain 
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therefore binds in the characteristic antiparallel orientation similar to cNOS isozymes.35 
Although the precise dynamics of CaM-mediated activation are not understood, it is known that 
CaM binding induces a conformational change that enables the flow of electrons between 
domains. NADPH, isozyme-specific residue Arg1400 and the C-terminal tail collectively repress 
enzyme activity by locking the FMN domain in place in an electron-accepting position. CaM 
binding propagates a large-scale swinging motion of the FMN domain in order to deliver 
electrons to the catalytic module.36 Following this, electrons flow from the FMN domain to the  
ferrous heme and reduce the molecular oxygen present, as shown in Figure 1.5.37 The reduced 
oxygen then cleaves the bond between guanadino-nitrogens and neighbouring protons and binds 
to these nitrogen atoms along with a proton on the L-arginine residue, producing the reaction  
 
Figure 1.5 Structures of domains NOS aligned by amino acid sequence.  
NOS domains with the FMN subdomain shown in yellow and the rest in grey, an a-helical CaM-
binding region with bound CaM and a dimeric heme domain. Electron transfer is represented by 
a green arrow. Reprinted from Li, J.; Zheng, H.; Feng, C. Deciphering Mechanism of 
Conformationally Controlled Electron Transfer in Nitric Oxide Synthases. Front. Biosci. - 
Landmark 2018, with permission for educational use from Frontiers in Bioscience.37  
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intermediate N-hydroxy-L-arginine (NOHA).38  In the second step of the reaction, NOHA is 
converted to L-citrulline and •NO via a similar reaction, where reduced oxygen cleaves the bond 
between •NO and its neighbouring carbon and proton atoms.39  
NOS is a homodimeric protein and requires dimerization into an active state, which 
involves interfacing large sections of the respective oxygenase domains. This interface includes 
the H4B  and L-arginine binding sites, a β-hairpin hook (N-terminal hook) as well as a structural 
zinc ion.27,40 This segment constitutes approximately 50 residues and is thought to stabilize inter- 
and intradimer H4B binding. Cysteine residues (two per monomer) are involved in coordinating 
H4B affinity, either through forming intermonomer disulphide bridges or ligating the tetrahedral 
zinc site between monomers.27 The N-terminal hook swaps recurrently between the two 
monomers, further stabilizing the formation of the dimer. This general description of active state 
dimerization of NOS is widely accepted, although the process varies slightly by isoform. Yeast 
two-hybrid studies have indicated that iNOS involves only oxygenase domain interactions 
whereas constitutive forms of NOS appear to interact at the reductase domain as well via 
interfacial salt bridges and hydrogen bonds.27,41,42  
Despite the utility of •NO produced from the various NOS catalytic pathways, excess 
•NO production has numerous physiological consequences. The study of the overexpression of 
nNOS is of particular clinical importance as it has been implicated in the pathogenesis of a 
variety of neurodegenerative conditions. 
 
1.3.2 Validation of nNOS as a Drug Target 
 Neurodegeneration is a broad term that refers to a loss of neuronal structure and 
function, characterizing many disorders including Alzheimer’s, Parkinson’s, epilepsy and 
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ischemic/traumatic brain injury among others.43 The loss of neuronal function cannot be 
attributed to a solitary pathway, and instead is the product of a complex cascade of biomolecular 
processes. One area of interest under investigation for the development of therapeutic 
intervention is the regulation of •NO levels in the brain. Acting as a secondary messenger, •NO 
operates through the cyclic-3’, 5’-monophosphate pathway and, in nanomolar concentrations, 
has been found to have neuroprotective properties. •NO in nerve cells is produced as holo-CaM 
activates nNOS following stimulation of Ca2+-permeable NMDA receptors.43,44 At basal levels, 
•NO related processes are important for long-term potentiation, learning and memory but can 
become neurotoxic when the delicate equilibrium in the cell is destabilized. These destabilizing 
factors include infarction, inflammation and excess NMDA receptor activation, which cause 
concentrations of •NO to surge in the brain by several orders of magnitude.45  
•NO can produce reactive nitrogen (RNS) and reactive oxygen (ROS) species such as 
peroxynitrite (ONOO-) and peroxynitrous acid (ONOOH).46,47 These free radicals can cause 
DNA damage, lipid peroxidation and protein structure damage through tyrosine nitration, excess 
S-nitrosylation and oxidation of cysteine residues.43 These in turn can result in function-
impairing protein misfolding and aggregation. Not only are the immediate effects of excess •NO 
problematic, but the physiological response via upregulation of various protective factors can be 
harmful as well. Subsequent depletion of glutathione stores and release of zinc from intracellular 
reserves can trigger apoptotic processes.48 The increase in DNA-repair mechanisms and the 
corresponding rise in energetic demand can lead to cell death. Excess •NO can also interfere with 
the mitochondrial electron transport chain which results in the further release of superoxide from 
mitochondria.43  
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There is a growing body of evidence suggesting that the confluence of effects seen from 
excess •NO production is linked to a number of neurodegenerative conditions. In the brains of 
Alzheimer’s patients, elevated •NO levels resulted in increased tyrosine nitration associated with 
protein damage and plaque build-up.49 In Parkinson’s mouse models, a ubiquitin ligase central to 
the survival of dopaminergic neurons is inactivated by •NO.50 nNOS also been shown to cause 
PTZ kindling epilepsy-induced endoplasmic reticulum stress and oxidative damage and is thus a 
valuable target for the development of treatments for chronic epilepsy patients.51 nNOS 
activation has also been shown to play a role in cell death in instances of ischemic brain injury.52 
There has been some research into the targeting and inhibition of nNOS for therapeutic uses. For 
example, nNOS-knockout mice models showed reduced neurological symptoms following 
induced ischemia. nNOS inhibitors have shown similar promise in models of Parkinson’s. In 
baboons with induced loss of dopamine and neurological changes, the administration of an 
somewhat selective nNOS inhibitor blocked dopamine depletion and cognitive impairment.53 A 
key criterion in the discovery of novel nNOS inhibitors is selectivity, as to minimize any 
potentially harmful nonspecific interactions. For example, the unwanted inhibition of eNOS has 
been correlated with congestive heart failure, cardiovascular dysfunction, myocardial fibrosis 
and should consequently be avoided.54,55 Among the most effective approaches in the selective 
inhibition of nNOS is to attenuate IET in the isozyme through the use of CaM antagonists. One 
such antagonist that has proven very successful in the selective inhibition of nNOS is the 






 TFP, shown in Figure 1.7A, is a phenothiazine derivative and is available commercially 
as a treatment for symptoms of schizophrenia. It has been well documented as a CaM antagonist 
and has been shown to block nNOS activity in vitro and in vivo.56 In one such study, a number of 
enzyme reactions were used to test the alteration of NOS sensitivity to CaM in pre-incubation 
preparation.57 The conversion of L-arginine to L-citrulline seen in vitro was significantly reduced 
by the presence of the antagonist. TFP has been shown to enact its therapeutic effect by reducing 
formation of RNS/ROS species and decreasing 3-nitro tyrosine.56 Binding conformation has been 
determined through various studies involving X-ray crystallography; TFP was shown to 
primarily interact with the C-terminal domain (Figure 1.7B).58,59 Thirteen residues form 191 
contacts between CaM and TFP, with only one of these residues (E11) being found on the N-
terminal domain.58 Stoichiometry of phenothiazine chemical class compounds including TFP 
ranges from 2-7 molecules per holo-CaM molecule, largely localized in or proximal to the 
hydrophobic regions of the globular domains.59  
Figure 1.6 Structure of TFP and the Holo-CaM-TFP Complex.  
(A) TFP structure (carbon in beige, hydrogen in white, nitrogen in blue, fluorine in green and 
sulphur in yellow). (B) Model of CaM bound to a single TFP molecule in the presence of Ca2+ 




 The potency of TFP makes it an effective inhibitor but bears with it the caveat of being 
rather cytotoxic. In addition to a long list of acute side effects, TFP has also been shown to 
inhibit DNA repair and increase instances of cell death of non-small cell lung carcinoma cells.60  
 
1.5 Melatonin and its Metabolites 
 Over the past two decades, there has been increasing evidence indicating that melatonin 
(aMT, N-acetyl-5-methoxytryptamine) and one of its metabolites may have the capacity to 
inhibit nNOS activity through a similar mechanism to TFP. 61–63 aMT is a melanophore-
contracting hormone synthesized by all vertebrates, produced primarily in the pineal gland but is 
also found in extrapineal locations such as the skin, gut, leukocytes and the Harderian gland. It is 
involved in numerous processes such as the entrainment of circadian rhythms, immune-
stimulation and cytoprotection.64,65 aMT is also present in fungi, protozoa, bacteria and 
invertebrates.66  
  aMT (Figure 1.6A) is an indoleamine with functional groups that confer specificity and 
amphiphilicity and is a derivative of tryptophan, biosynthesized via 5-hydroxylation, N-
acetylation, decarboxylation and O-methylation. It is highly pleiotropic and targets the 
mammalian MT1 and MT2 Gi protein-coupled membrane receptors. There are considerable 
differences in location and density of these melatonin receptor subtypes, but both contribute to 
circadian feedback in the suprachiasmatic nucleus (SCN), or “circadian pacemaker”.67 MT1 
receptors primarily modulate neuronal firing, vasoconstriction, and cancerous cell proliferation 
in addition to performing various metabolic functions. They are expressed in the pars tuberalis of 
the pituitary gland, the retina and the SCN. MT2 receptors are expressed in the retina and are 
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responsible for phase-shift of circadian rhythms, vasodilation and enhancing immune response.68 
Both receptors have been shown to have inhibitory effects on the cAMP pathway.69  
 Circulating hormonal aMT is predominantly catabolized by P450 monooxygenases to 
produce 6-hydroxymelatonin, which is then conjugated to form the 6-sulfatoxymelatonin 
metabolite. In tissue aMT, and in the central nervous system in particular, oxidative pyrole-ring 
cleavage results in the formation of alternate metabolites, namely N1-acetyl-N2-formyl-5-
methoxykynuramine (AFMK, Figure 1.6B), which is deformylated to form N1-acetyl-5- 
methoxykynuramine (AMK, Figure 1.6C).70 
 
 
There have been many studies interrogating the interaction between CaM and aMT and 
its impact on nNOS enzyme activity. There appears to be a great amount of uncertainty as to the 
biological relevance of these interactions, primarily due to the disconnect between the very weak 
CaM-aMT binding observed experimentally and the significant inhibitory effects of aMT on 
nNOS seen in vivo and in vitro. 
Interest in aMT as a CaM antagonist was possibly first generated by studies involving 
biological samples of CaM that reported very high-affinity binding (Kd = 0.2 – 1 nM).71,72 
Figure 1.7 Structures of aMT, AFMK and AMK. 
Molecular structure of (A) aMT and (B) AFMK and (C) AMK with white corresponding to 
hydrogen atoms, blue to nitrogen atoms, red to oxygen atoms and beige to carbon atoms. 
Models were derived from PubChem CID 896, 171161 and 390658 respectively and visualized 
using UCSF Chimera v. 1.13.1. 
A B C 
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Subsequent analyses involving purified CaM samples suggested that binding is much weaker. In 
one such study, 15N-HSQC nuclear magnetic resonance (NMR) spectroscopy titrations showed 
only minor perturbation of chemical shifts in CaM, consistent with a Kd value in the millimolar 
range.73 Fluorescence and far-UV circular dichroism experiments from the same group showed 
similarly weak behaviour, with no saturation of CaM achieved even at high concentrations of 
aMT.73 A later study used 15N-HSQC NMR titrations in addition to computational methods and 
arrived at the same conclusion.74 Non-linear fitting curves from their NMR titrations showed 
comparable affinities between globular domains, with Kd values ranging from approximately 3-6 
mM. Their molecular dynamics simulations revealed highly dynamic binding between CaM and 
aMT, with the ligand localized primarily within the hydrophobic cavity of the C-terminal 
domain. Various groups have used gel mobility assays to further analyze association, with 
changes in the electrophoretic mobility of CaM typically only occurring at high concentrations (1 
mM) of aMT.73,75 The cause of the discrepancy between the apparent affinities of biological and 
purified CaM samples remains unknown. 
The understated nature of the CaM-aMT complex formation contrasts the significant 
inhibition of nNOS enzyme activity reported in vivo and in vitro. Pozo et al. observed the effect 
of aMT on nNOS activity by monitoring the conversion of L-arginine to L-citrulline in rat 
cerebellar homogenates.75 The presence of 1 mM melatonin lowered Vmax values from 90.9 
pmol/mg protein/min to 65.5 pmol/mg protein/min. Antagonism of holo-CaM was suggested by 
a reversal of inhibition by the presence of the Ca2+ chelator EGTA or the addition of exogenous 
CaM to the incubation medium. Leon et al. similarly used homogenates from rat striatum to 
analyze kinetics of enzyme-substrate reactions in the presence of aMT.61 The ligand was shown 
to inhibit nNOS activity via non-competitive antagonism of CaM. Homogenates of rat striatum 
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were used to similar effect to analyze the effect of AMK on enzymatic activity.62 It was found 
that AMK acts non-competitively as previously described in the case of aMT, but no inhibition 
was caused by AFMK. 
 Camacho et al. extended their research beyond naturally occurring metabolites and 
evaluated synthetic analogues of aMT based on the excitatory response of striatal neurons to 
sensorimotor cortex (SMCx) stimulation.63 These analogues consisted of kynurenine, 
kynuramine and phenyl-pyrazole structures with a variety of substituted R-groups and 
comparative analyses between these compounds revealed trends in structure-dependent 
inhibitory response. Compounds, specifically kynurenines and kynuramines, in which the 2’-
NH2 group was eliminated or blocked with either benzyl or dimethyl groups were significantly 
less effective in attenuating nNOS, as the amide potentially acts as a stabilizing intramolecular 
hydrogen donor. Similarly, compounds lacking 5’-Ome or Cl groups showed diminished levels 
of inhibition, although the nature of the interaction (hydrophobic or electrostatic) is not known. 
This structure-related inhibition of nNOS shows promise for developing additional analogues 
possessing diverse structural elements to achieve greater degrees of specificity and can be 
compared for their potency relative to other known antagonists.  
 Developing a detailed structural understanding of how these prospective antagonists, and 
particularly AMK due to its higher purported capacity for inhibition, interact with CaM and 
nNOS is of significant value. This is especially true in the case of AMK, as there is little in the 
way of any structural information of how it interacts with CaM. To this end, there are many 




1.5 NMR Spectroscopy 
 NMR spectroscopy has been used to determine high-resolution 3D structures and monitor 
internal dynamics of a protein.76,77 NMR produces structures comparable to X-ray 
crystallography, however it can determine structures of proteins and molecules that would be 
unable to crystallize due to intrinsic flexibility and mobility. NMR is not without its caveats, as 
protein samples for NMR require isotopic labelling, such as 15N and 13C, which are rather costly 
to synthesize. Furthermore, analysis of large protein structures by NMR is difficult due to 
chemical shift overlap and lower sensitivity.  
 In an NMR experiment, the protein sample is placed in a static magnetic field and 
irradiated using radiofrequency (RF) pulses, perturbing the nuclei of the sample, which in turn 
produces an electromagnetic signal with a frequency specific to the magnetic field of the 
nucleus. This signal is produced by a net voltage in a detection coil by precession of nuclear 
spins around the constant magnetic field, typically at the nuclei’s intrinsic Larmour frequency. 
The first step in structure determination is the complete assignment of the 1H spectrum of the 
given protein, followed by the assignment of nuclear Overhauser enhancement (NOE) 
interactions. The more NOE constraints, the higher the resolution of the 3D structure (James and 
Oppenheimer, 1994). This is due to dipolar coupling through space between nuclei, rather than 
spin-spin coupling through chemical bonds.  
 Despite the utility of NMR, limitations arise with larger proteins due to severe crowding 
and chemical shift degeneracy. This makes both sequential and long-range NOE assignment 
nearly impossible. Furthermore, there is a pronounced increase in rotational correlation time, 
which corresponds to longer relaxation times and an increase in line widths. All scalar 
correlation experiments are contingent on the line widths not being significantly greater than the 
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size of J-couplings, which makes the labelling of proton spin systems extremely difficult.78 3D 
NMR experiments have been able to assist in overcoming these issues, expanding 2D spectra 
into a 3rd dimension which can then resolve overlap through separation into distinct layers. 
The 2D 15N-heteronuclear single quantum coherence (15N-HSQC) experiment is one of 
the most frequently employed protein NMR experiments. Each residue of a protein except 
proline has an amide proton attached to a nitrogen in the peptide bond (Figure 1.5B). HSQC 
correlates the nitrogen atom and the amide proton to yield a peak in the HSQC spectrum. The 
15N-HSQC cannot be used to assign specific residues on its own and therefore is used in 
conjunction with various 3D experiments. These experiments can collectively be used to assign 
1H, 13C, and 15N chemical shifts for the protein. The following step involves the spatial couplings 
between nuclei, determined using nuclear Overhauser effect spectroscopy (NOESY), which 
infers distance constraints. NOESY spectra show NOE cross peaks of proximal nuclei, usually 
within 5 Å in a folded protein structure.76  
There is significant interest in understanding the structural basis for interactions between 
potential antagonists, CaM and NOS. Despite numerous studies suggesting isoform-
dependent properties of AMK, there are no 3D structures of CaM-AMK or CaM-AMK-NOS 
complexes. It is possible that they attenuate NOS activity through unfavourable modifications of 
this complex by affecting key residues in the N- and C-terminal lobes of CaM. Although aMT 
and AMK possess the intrinsic hydrophobicity characteristics of known CaM antagonists such as 
TFP, it is unclear which structural elements form contacts with CaM and with which residues. 
Elucidating the specific nature of this interaction using NMR may, however, may prove difficult 
given the putative millimolar range dissociation constant  (Kd) of aMT binding with CaM.73,74 As 
such it is unclear whether NOE-based methods of structure determination are sensitive enough 
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for such a potentially weak system. Computational methods may be used to compliment NMR 
data in order to overcome this obstacle. 
 
1.6 Molecular Docking and Dynamics Simulations 
Protein-ligand interactions have been at the forefront of drug discovery and design as 
they are a prerequisite for biological regulation.79,80 Molecular docking experiments have proven 
to be a simple and economic way of characterizing these interactions, predicting experimental 
binding modes and affinities of small molecules within the bounds of a particular receptor 
target.79 The quality of the output relies on the optimization search method and the scoring 
functions by which generated poses are evaluated. These functions are diverse, including 
knowledge-based, empirical and force field-based algorithms.81 Docking software frequently use 
a rigid docking model in addition to semi-flexible model with mobile sidechains. There are also 
docking models in which the receptor is assumed to be entirely flexible, although these are less 
well developed.79,82 Molecular docking can operate independently as a less refined approach to 
exploring protein-ligand interactions, or serve as a necessary precursor for more advanced and 









V = Vbonded + Vnonbonded 
 
Vbonded = ∑bonds Kb(b− b0)2+ ∑angles Kθ(θ− θ0)2 + ∑dihedralsKχ(1+cos(nχ− δ)) 
 
Vnonbonded = ∑nonbonded pairs ij (qiqj/εrij) +∑nonbonded pairs ij εij[(Rmin, ij/rij)12−2(Rmin, ij/ rij)6 ] 
 
 Figure 1.8 Molecular mechanics of the CHARMM [78] forcefield.  
 
Basic components of the CHARMM [78] forcefield where Kb, Kq and Kc are the bond, angle and 
torsional force constants. B, q and c are bond length, bond angle and dihedral angle. n is 
multiplicity and δ the phase of the torsional periodic function; rij is the distance between 
atoms i and j; qi and qj are the partial charges of atoms i and j; ε is the effective dielectric constant; 





Molecular dynamics is a computational method that simulates the motion of a molecular 
system over a function of time.83 All atoms within the simulation box are computed by the 
integration of Newtonian equations of motion as described in the equation d2ri(t)/dt2 = Fi(t)/mi.81 
Fi(t) is the force exerted on atom i at time t, ri(t) the vector position of the atom i at time t and mi 
is the mass of the atom. There are many integration algorithms that derive classical mechanical 
equations by discrete-time numerical approximation. The most commonly applied force fields in 
MD simulations are CHARMM, GROMOS, OPLS and AMBER.84–87 An example of the basic 
components of the CHARMM force field is seen in Figure 1.8.81 The trajectories over a specified 
timescale can then be visualized and analyzed according to various user-specified parameters. 
The ensemble of molecular docking and dynamics simulations paired with experimental methods 
are capable of generating a comprehensive analysis of complex biomolecular systems.     
 
1.7 Research Objectives 
The purpose of this thesis was to elucidate the structural means by which AMK might 
antagonize CaM in the isoform specific inhibition of nNOS. This was accomplished by: 
1. Using biophysical analyses to characterize the strength of interaction between CaM 
and AMK and test for AMK-mediated reduction in CaM’s affinity to NOS isoforms.  
2. Interpreting AMK-induced chemical shift perturbations of isotopically labelled CaM 
to reveal the structural trends involved in complexation and to quantitatively measure 
affinity. 
3. Determining solution structures of CaM when bound to AMK to reveal 
conformational changes that may be responsible for inhibitory function.  
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4. Using computational methods to visualize the dynamic interplay between CaM and 
AMK and replicate complex CaM-AMK-NOS systems to observe competition on a 
nanosecond timescale.    
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Chapter 2  
Biophysical Characterization of AMK interactions with 
 CaM and NOS Peptides 
 
2.1 Introduction  
Several studies have suggested that aMT and one of its metabolites, AMK, act as CaM 
antagonists and selectively inhibit nNOS.61–63 This would prove significant as these naturally 
occurring compounds would offer far less cytotoxic alternatives to compounds such as TFP. 
Despite the purported ability of AMK to inhibit nNOS in vitro and in vivo, there is minimal data 
available that provides a detailed characterization of its binding with CaM as to better understand 
its mechanism of action. There are, however, studies available that interrogate the interaction 
between CaM and aMT that can provide insight into how structurally similar compounds may 
behave. Interest in aMT as a CaM antagonist was perhaps initiated by a study that reported a site-
specific Kd value to be approximately 188 pM, however these findings appear to be an 
anomaly.71 In a 1998 study, aMT showed minimal perturbation of CaM’s methionine crosspeaks 
in NMR studies.73 Furthermore, circular dichroism results from the same paper showed no 
significant impact on secondary structure. Electrophoretic mobility of CaM in gel mobility 
assays was only altered by aMT at extremely high concentrations of the ligand. In a later study, 
fluorescence assays showed no saturable association, even at elevated concentrations of aMT.74 
This was reflected in 15N-HSQC NMR titration data in which changes in chemical shifts 
occurred in fast exchange on the NMR timescale, consistent with rapid association and 
dissociation. Fitting curves from this titration produced using non-linear regression revealed a 
millimolar range affinity.  
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 In the present study, the goal is to build upon previous research into aMT and AMK and 
develop a holistic array of biophysical analyses to further investigate their potential as 
therapeutic agents. A particular focus was given to AMK, which was determined experimentally 
to be more potent that aMT and other structurally similar kynurenines. 61–63 The strength of 
binding was qualitatively and quantitatively defined using gel mobility assays, isothermal 
titration calorimetry (ITC), surface plasmon resonance (SPR) and circular dichroism (CD). The 
latter also used to observe any aMT- or AMK-mediated changes in secondary or tertiary 
structure in CaM. Effects on nNOS enzymatic activity were measured in vitro using the 
oxyhemoglobin capture assay.  
 
2.2 Methods and Experiments 
2.2.1 Wildtype CaM Protein Expression 
The pET9d vector was used to express wildtype rat CaM with restriction enzymes NcoI 
and BaMHI used to clone in the CaM sequence. pET9d was then transformed into competent 
BL21 de3 E. coli cells. 
 A starter culture containing a colony of transformed E. coli, 50 μL of kanamycin and 50 
mL of lysogeny broth (LB) was incubated overnight. 10 mL of this solution was then added to 4 
L flasks each containing 1 L LB. Following a period of incubation where a differential 
absorbance of 0.6-0.8 at 600 nm was achieved, the culture was induced with 1 mL of 0.5 M 
IPTG and incubated for 4 hours. The solution was then centrifuged at 5000 rpm at 4 °C for 5 
minutes. The supernatant was removed, and the pellets were collected and stored at -80 °C. 
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2.2.2 Purification of Wildtype CaM 
Cells were suspended in 4 volumes of 50 mM MOPS, 1 mM EDTA, 1 mM dithiothreitol 
(DTT), 100 mM KCl, pH 7.5 and then lysed with an Avestin EmulsiFlex-C5 homogenizer 
(Ottawa, ON). The resulting lysate was centrifuged at 48000 x g for 30 minutes at 4 °C and 5 
mM CaCl2 was then added. The supernatant was loaded onto a phenyl sepharose fast flow resin 
(GE Healthcare Bio-Sciences, Baie d’Urfe, PQ) and connected to the Äkta design system in a 1 
cm x 10 cm column (GE Healthcare Bio-Sciences, Baie d’Urfe, PQ). This column was 
equilibrated with 50 mM Tris-HCl, 1 mM CaCl2, pH 7.5. 5 volumes of this same buffer were 
then used to wash the resin, followed by 3 volumes of 50 mM Tris-HCL, 1 mM CaCl2, 500 mM 
NaCl, pH 7.5. The final wash consisted of 3 volumes of 50 mM Tris-HCL, 1 mM CaCl2, pH 7.5. 
CaM was eluted from the resin with 10 mM Tris-HCL, 10 mM EDTA, pH 7.5 and collected in 2 
mL fractions, which were then scanned from 320 to 250 nm by a Varian Cary UV–visible 
Spectrophotometer (Varian, Mississauga, ON). The fractions of CaM (e = 3229 M-1 L-1) that 
displayed the characteristic peaks at 277 nm (tyrosine residues) and 269, 265, 259 and 253 nm 
(phenylalanine residues) were collected into aliquots of 500 μL. Purity was verified using 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS PAGE). 
 
2.2.3 NOS CaM-Binding Domain Peptides 
All experiments were conducted using the CaM-binding domain peptides of NOS (Figure 
2.1). Bovine eNOS (RKKT FKEVA NAVKIS ASLM, residues 491- 510), rat nNOS (KRRAI 
GFKKL AEAVK FSAKL MGQAK RVC, residues 730–757) and human iNOS (RPKRR EIPLK 
VLVKA VLFAC MLMRK, residues 508–531) peptides were synthesized by SynPeP (SynPeP 








2.2.4 Circular Dichroism Spectroscopy 
All circular dichroism (CD) experiments were performed using a Jasco J-715 CD 
spectropolarimeter and analyzed using J-715 software (Jasco Inc., Easton, MD, USA) as 
previously described with some modifications.88 Samples were measured in a 1 mm quartz 
cuvette (Hellma, Concord, ON) and kept at 25°C using a Peltier type constant-temperature cell 
holder (model PFD 3505, Jasco, Easton, MD). All samples were in a 20 mM TrisHCl 100 mM 
KCl buffer with 1 mM CaCl2 and incubated for 20 minutes at room temperature before loading. 
Far-UV spectra were recorded over a 260-200 nm range with a CaM concentration of 12 µM. 
Near-UV spectra were recorded over a range of 300-250 nm range with a CaM concentration of 
70 µM. All spectra were recorded with a 1.0 nm band width, 0.2 nm resolution, 100 mdeg 
sensitivity at a 0.125 s response and a rate of 100 nm/min with a total of 25 accumulations. 
 
2.2.5 Isothermal Titration Calorimetry 
All isothermal titration (ITC) recordings were performed on a Microcal ITC200 from 
Microcal (Northampton, MA) at 25°C, 750 rpm stir speed, and reference power set between 1 
and 2 µcal/s. Experiments were conducted in 50 mM HEPES buffer pH 6.95, 150 mM KCl and 2 
mM CaCl2, in both the cell and syringe. Buffer into buffer, antagonist into buffer, peptide into 
eNOS 
(human) 
  RKKTFKEVANAVKISASLM 491-510 
nNOS) 
(human) 
  KRRAIGFKKLAEAVKFSAKLMGQAKRVC  730-757 
iNOS 
(human) 
  RPKRREIPLKVLVKAVLFACMLMRK 508-531 
Figure 2.1 Sequence of CaM-binding domains of NOS isoforms. 
The CaM-binding domain sequences for bovine eNOS, rat nNOS and human iNOS are shown. 
Acidic and basic residues are shown in red and blue respectively. 
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buffer and buffer into CaM controls showed relatively low, consistent heats of injection and no 
significant baseline decay or drift indicating adequately matched cell and syringe buffer 
conditions. For CaM-NOS peptide control experiments, 39 µL of each peptide was titrated into 
202 µL of CaM at varying concentrations, generally ranging from 100 µM peptide into 10 µM 
CaM to 500 µM peptide into 50 µM CaM. For CaM-AMK ITC experiments, AMK in the 
syringe at concentrations up to 2 mM was titrated into the cell containing 10 µM CaM. Ideal 
starting conditions were determined empirically depending on anticipated strength of binding 
and signal intensity. Between 50-100 injections at 3-minute intervals were carried out for a 
typical experiment. For competition assays, CaM was incubated with a 100-fold excess of AMK 
for 20 minutes at room temperature prior to loading into the cell and NOS peptide was titrated as 
previously described. Differences between the isotherms with and without AMK present were 
used to indirectly measure Kd values of AMK-CaM complexation according to KB = 
([KA/KAapp]-1)(1/Bt). KA and KB represent the binding constants for the NOS peptide and AMK 
respectively, KAapp is the experimentally measured binding constant for NOS in the presence of a 
given AMK concentration, and Bt corresponds to AMK concentration. Data analysis was 
performed using Origin ITC200 Origin70 module with pre-loaded fitting equations for one- and 
two-site models. The one-set-of-sites model was found to be applicable to all experiments.  
 
2.2.6 Gel Mobility Assays 
The binding between CaM, NOS and antagonists were assayed by observing relative 
mobility shifts of CaM by urea polyacrylamide gel electrophoresis (urea PAGE) and native gels. 
Gels contained 15% acrylamide, 0.375 M Tris-HCl, 1 mM CaCl2 and varying urea 
concentrations ranging from 0-8M. Gels were run under a constant voltage of 100V in an 
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electrophoresis buffer containing 25 mM Tris-HCl, 1 mM CaCl2 and 192 mM glycine. Samples 
contained urea (with the concentration matching that of the gel), 100 mM Tris-HCl (pH 7.5), 1 
mM CaCl2 and 20 μM CaM in a 15 μL sample volume and were incubated for 1 hour following 
centrifugation followed by a half volume addition of 50% glycerol with bromophenol blue. 10 
μL of each sample was added to each well of the gel. In CaM binding experiments, between 1-
1000 equivalents of AMK, aMT and TFP were added to individual samples. In competition 
experiments, AMK, aMT and TFP were added to samples in addition to 20 μM of NOS peptide. 
 
2.2.7 Surface Plasmon Resonance 
All surface plasmon resonance (SPR) experiments were conducted by Victoria Robertson 
as part of her 4th year thesis project under the supervision of Dr. J.G. Guillemette. 
 
2.2.7.1 Sample Preparation for SPR 
1X phosphate buffered saline pH 7.4 with 0.05% tween (PBS-T) was acquired from 
Nicoyalife (Kitchener, ON). Cysteamine (Cys) was prepared for immobilization at a 
concentration of 100 mM in PBS-T. This was then used to make 5:1 Cys:NOS peptide for 
injection.  
 A working stock of 33.3 µM CaM was stored in PBS-T and 100 µM CaCl2 (PBS-T-
CaCl2). CaM experiments without AMK were conducted using 1 mL of 333 nM CaM, prepared 
with 10 µL of 33.3 µM CaM and 990 µL PBS-T-CaCl2. This solution was then diluted as needed 
with PBS-T-CaCl2 to obtain 300 µL of each 25, 50, 100, 150, 200, 250, 333 nM CaM solutions. 
AMK was dissolved into PBS-T-CaCl2 to make 200 µL of 20 mM solution. CaM with excess 
AMK solution was prepared with 10 µL of 33.3 µM CaM, varying volumes of 20 mM AMK 
 29 
depending on desired antagonist concentration, and the solution was brought up to a final volume 
of 1 mL with PBS-T-CaCl2. CaM was incubated with AMK at room temperature for a minimum 
of 20 minutes, then diluted as needed with PBS-T-CaCl2 to obtain 300 µL of each 25, 50, 100, 
150, 200, 250, 333 nM CaM solutions with excess AMK. 
 
2.2.7.2 SPR Protocol 
 SPR experiments were conducted using and openSPR instrument (Nicoylife, Kitchener, 
ON) at 25 °C at a constant 50µL/min flow rate in a 100 µL injection loop. The NOS peptides 
capped with an N-terminal cysteine were bound to a gold nanoparticle sensor chip functionalized 
with an immobilized coating of Cys. Binding of CaM in the presence and absence of AMK was 
analyzed in a Ca2+-saturating PBS-T-CaCl2 buffer. CaM was injected over the Cys:NOS peptide 
at concentrations ranging from 25-333 nM for 2 minutes to allow association to occur. Following 
each CaM injection at a given concentration, PBS-T buffer with 100 mM EDTA was injected to 
completely dissociate CaM and regenerate the unbound NOS peptide. Analysis of the data was 
done with TraceDrawer software (Ridgeview Instruments). Kinetics parameters  
250-300 µL of injection solution was prepared for an OpenSPR 100 µL injection loop. 
The SPR system was primed with PBS-T buffer, referenced and inserted onto a clean gold 
nanoparticle sensor chip. Experiments were conducted with PBS-T buffer at a flow rate of 150 
µL/min for 10 minutes prior to injection with 80% IPA for 5 minutes. Two PBS-T buffer blanks 
were injected at 150 µL/min, followed by a change in flow rate to 50 µL/min for up to 3 
injection until no signal (<0.01 nm) was observed. Cys (1 mM) was injected and the buffer was 
changed to PBS-T-CaCl2 after a 5-minute period for equilibration. Buffer was injected 2-4 times 
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until no signal was observed. Analyte was then injected in decreasing concentrations separated 
by rinses consisting of PBS-T-CaCl2, PBS-T-EDTA and then PBS-T-CaCl2 again.  
 
2.2.8 Enzyme Kinetics Assays 
All enzyme kinetics experiments were conducted by Joe Bui as part of his 4th year thesis 
project under the supervision of Dr. J.G. Guillemette. 
 
2.2.8.1 Oxyhemoglobin Preparation 
A 15 mL falcon tube was filled with approximately 5mL of bovine hemoglobin (Hb) was 
dissolved in the minimal amount ( ~2.5 mL) of 50 mM TRIS-HCl, pH 7.5 at room temperature. 
40 mg of sodium hydrosulphite (purged with N2 and desiccated) was added to the solution and 
inverted to mix the sample. This was followed by a colour change of dark brown to ruby red. 
PD-10 (GE Healthcare Bio-Sciences, Baie d’Urfe, PQ) columns were washed with 25 mL of 
Milli-Q water and then equilibrated with 25 mL 50 mM TRIS-HCl, pH 7.5 at room temperature. 
1 mL of Hb solution was loaded onto each PD-10 column to remove the sodium hydrosulphite 
from solution. The ruby red oxyhemoglobin (oxyHb) was eluted last, with the last few drops 
visible in the column not being collected to avoid contamination with residual sodium 
hydrosulfite.  Solutions containing 25 µL of concentration Hb solution and 975 µL of 50 mM 
TRIS-HCl, pH 7.5 at room temperature in 0.2 cm quartz cuvettes were scanned from 220 to 700 
nm on a UV-Vis spectrometer, using 1 mL 50 mM TRIS-HCl, pH 7.5 as a blank. Finally, the Hb 
solutions were aliquoted in 200 µL portions into Eppendorf tubes, flash frozen using dry ice, and 
stored at -80 °C. The concentration of oxyHb was determined using the following equation: 
[HbO4] μM = (1.013 x A576 – 0.3269 x A630 – 0.7353 x A560) x 100 x dil. factor x 5, where 
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A560, A576 and A630 correspond to absorbance values and 560, 576 and 630 nm respectively. The 
5 is present on account of a 0.2 cm pathlength and the 100 is from a previously published 
equation based on known extinction coefficients of oxyHb.89,90 
 
 
2.2.8.2 Oxyhemoglobin Calibration 
The molar extinction coefficient for the conversion of oxyHb to metHb for the oxyHb 
capture assay was calculated according to a previously published method.91 Potassium 
ferricyanide (K3[Fe(CN)6]) was used to oxidize oxyHb to metHb. 40 mg of K3[Fe(CN)6] was 
dissolved in 10 mL of 50 mM Tris-HCL pH 7.5 at room temperature  to produce a 12 mM stock, 
which was then diluted 10-fold with 50 mM Tris-HCl to produce a final stock concentration of 
1.2 mM K3[Fe(CN)6]. The oxyHb solution was diluted to 40 µM in 50 mM Tris-HCl pH 7.5 at 
room temperature to produce the working oxyHb solution. The metHb working solution was 
prepared by diluting oxyHb to 40 µM in the presence of 0.12 mM K3[Fe(CN)6]. 200 µL of each 
working solution was then added to a 96 well microlitre plate, with oxyHb loaded into wells A1-
3 and metHb into wells A4-6. 100 µL of 50 mM Tris-HCl pH 7.5 was added to columns 1-3 of 
rows B-H, and 100 µL of 50 mM Tris-HCl pH 7.5, 0.12 mM K3[Fe(CN)6] was added to columns 
4-6 of rows B-H. Triplicate serial dilutions where then performed using a multi-channel pipettor 
by transferring 100 µL of row A to row B, row B to row C and so on until row G, with the final 
100 µL taken being discarded and Row H being used as a blank. The plate was read using a 
SpectraMax 384 Plus 96 well UV-vis spectrophotometer and SoftMax Pro software (Molecular 
Devices, Sunnyvale, CA) at 401 nm. The slopes of OD401 versus nM of Hb was calculated for 
metHb and oxyHb and used to determine the extinction coefficient  
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De nm (met- to 0xyHb) needed for the oxyHb capture assay. The value of the extinction coefficient 
ranged from 0.10 to 0.13 OD401 per nM.  
 
2.2.8.3 Oxyhemoglobin Capture Assay 
Initial rates of •NO production were measured using the spectrophotometric 
oxyhemoglobin capture assay following a similar method as one previously developed by Dr. 
Basil Perdicakis (PhD. 2003, University of Waterloo) and Dr. Heather Montgomery (PhD. 2003, 
University of Waterloo) based on previous methods.91 The experiment was conducted through 
the analysis of a 96 well microlitre plate containing mixtures of two solutions: the enzyme and 
substrate solutions. The nNOS enzyme was previously made by Dr. Valentina Taiakina, a 
previous graduate student, via recombinant protein expression. The substrate solution contained 
glycerol, Tris-HCl pH 7.5, CaCl2, superoxide dismutase (SOD), catalase, bovine serum albumin 
(BSA), NADPH, L-arginine, and oxyHb. The enzyme solutions contained the nNOS enzyme, 
FAD, FMN, H4B, DTT, BSA, catalase, SOD, Tris-HCl pH 7.5, and glycerol. NADPH, H4B and 
DTT were prepared fresh on the day of the assay, with H4B being dissolved in 20 mM DTT to 
ensure it was properly reduced upon solvation. NADPH serves the purpose of reacting with 
residual L-arginine in the enzyme solution from the NOS dialysis buffer. Catalase and SOD are 
present to react with reactive oxygen species resulting from uncoupled electron transfer in 
NOS.90 Glycerol and BSA maintain stability of the NOS enzyme during the assay. 
Enzyme-initiated assays involved the transfer of a CaM-AMK mix into enzyme solution, 
which was then pipetted into the substrate solution. In a 96 well microlitre plate, 100 µL of the 
enzyme solution was incubated for 5 minutes at room temperature in columns 5-6 with 40 µL of 
solution containing either CaM alone or CaM pre-incubated with antagonist. When no CaM is 
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needed, the CaM was replaced by Tris-HCl pH 7.5. During these 5 minutes, 40 µL of substrate 
was added to columns 1-4. Following incubation, 60 µL of the enzyme-CaM mixture was 
transferred to the substrate solution, with column 5 being transferred to column 1-2 and column 6 
to 3-4. In a typical experiment, each row of the plate corresponds to a different CaM 
concentration increasing from 0 to 30 nM at a given concentration of antagonist, with row H 
being reserved for a control in which enzyme activity is blocked partially or completely by 
EDTA or a potent inhibitor. The final reaction mixture contained 1 µM FAD, 1 µM FMN, 5 µM 
H4B, 1 µM DTT, 450 µM NADPH, 0.2 mg/mL BSA, 50 U/mL catalase, 100 U/mL SOD, 30 nM 
nNOS, 5 µM oxyHb, 25 µM, L-arginine, 200 µM CaCl2, 50 mM Tris-HCl pH 7.5 and 1% 






 Stock Concentration Mix 
Concentration  
Volume of Stock for 1 Well 
(µL) 
Final Concentration in Reaction 
Well 
HbO4^ 1314 µM 12.5 µM 0.381 5 µM 
L-Arginine^ 30000 µM 62.5 µM 0.0833 25 µM 
NADPH* 10000 µM 450 µM 1.8 450 µM 
BSA* 100 mg/mL 0.2 mg/mL 0.08 0.2 mg/mL 
Catalase* 89700 U/mL 50 U/mL 0.022 50 U/mL 
SOD* 3100 U/mL 100 U/mL 1.29 100 U/mL 
CaCl2^ 20000 µM 500 µM 1 200 µM 
Tris-HCl pH 7.5 50 mM 50 mM 33.3 50 mM 
Glycerol* 20% 1% 2 1% 
 Stock Concentration Mix 
Concentration  
Volume of Stock for 1 Well 
(µL) 
Final Concentration in Reaction 
Well 
nNOS^ 1314 µM 0.070 µM 0.070 0.030 µM 
FAD^ 1507 µM 2.33 µM 0.155 1 µM 
FMN^ 1307 µM 2.33 µM 0.178 1 µM 
H4B^ 6400 µM 11.66 µM 0.182 5 µM 
DTT^ 20000 µM 2.33 µM 0.0117 1 µM 
NADPH* 10000 µM 630.25 µM 6.30 450 µM 
BSA* 100 mg/mL 0.28 mg/mL 0.28 0.2 mg/mL 
Catalase* 89700 U/mL 70.03 U/mL 0.0781 50 µM 
SOD* 3100 U/mL 140.06 U/mL 4.52 100 U/mL 
Tris-HCl pH 7.5 50 mM 50 mM 81.3 50 mM 
Glycerol 20% 1.4% 7 1% 
^Dilution factor of 0.429 to account for dilution upon mixing with CaM solution and substrate solution. 
*Dilution factor of 0.714, constituents are also found in the substrate solution thus dilution only occurs from adding the CaM-inhibitor mixture. 
 
Table 2.1 Substrate solution of enzyme-initiated assays 
 
Table 2.2 Enzyme solution of enzyme-initiated assays 
 
^Dilution factor of 0.429 to account for dilution upon mixing with CaM solution and substrate solution 
*Dilution factor of 0.714, constituents are also found in the substrate solution thus dilution only occurs from adding the CaM-inhibitor mixture. 
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Substrate-initiated assays involved the transfer an nNOS-AMK mix into the enzyme 
solution, which was then transferred to the substrate solution containing CaM. In a 96 well plate, 
40 µL of enzyme solution was incubated at room temperature in column 7 with an nNOS-AMK 
mixture for 10 minutes. For reactions with no AMK present, Tris-HCl pH 7.5 was used in place 
of the antagonist. During this incubation period, 210 µL from each substrate solutions containing 
varying CaM concentrations were aliquoted into column 5-6. Each row corresponded to a given 
CaM concentration, typically ranging from 0 to 30 nM. 20 µL of the enzyme solution was then 
pipetted into columns 1-4 and the reaction was initiated by transferring 80 µL of substrate from 
column 5 into columns 1-2, and 80 µL form column 6 to columns 3-4. The final reaction mixture 
contained 1 µM FAD, 1 µM FMN, 5 µM H4B, 1 µM DTT, 450 µM NADPH, 0.2 mg/mL BSA, 
50 U/mL catalase, 100 U/mL SOD, 30 nM nNOS, 5 µM oxyHb, 25 µM, L-arginine, 200 µM 







 Stock Concentration Mix 
Concentration  
Volume of Stock for 1 Well 
(µL) 
Final Concentration in Reaction 
Well 
HbO4^ 1314 µM 6.25 µM 1.00 5 µM 
L-Arginine^ 30000 µM 31.25 µM 0.219 25 µM 
NADPH* 10000 µM 450 µM 9.45 450 µM 
BSA* 100 mg/mL 0.2 mg/mL 0.42 0.2 mg/mL 
Catalase* 89700 U/mL 50 U/mL 0.117 50 U/mL 
SOD* 3100 U/mL 100 U/mL 6.77 100 U/mL 
CaCl2^ 20000 µM 250 µM 2.625 200 µM 
CaM 20000 µM Variable Variable Variable 
Tris-HCl pH 7.5 50 mM 50 mM Fill to 210 µL total volume 50 mM 
Glycerol* 20% 1% 10.5 1% 
Table 2.1 Substrate solution of substrate-initiated assays 
 
^Dilution factor of 0.8 to account for dilution when added with the enzyme solution. 






After initiation, the plate was read at 25 °C in a SpectraMax 384 Plus 96 well UV-vis 
spectrophotometer using SoftMax Pro software (Molecular Devices, Sunnyvale, CA). The 
reactions were read at 401 nm at 7 second intervals for 5 minutes. Soft Max pro was used to 
convert absorbance rates to catalytic activity according to the equation Activity = v x 60 s • min-1 
/ De401 nm (met- to oxyHb) / (well volume x [nNOS] in nM x nNOS molecular weight in g/mol x 1000 
mg/g) where v represents of slope of the change in absorbance over time in seconds. Activity is 
expressed in nanomoles of •NO produced per minute per milligram of enzyme (nmol •NO min-1 
mg-1). 
 
2.3 Results and Discussion 
2.3.1 Circular Dichroism Spectroscopy 
Circular Dichroism (CD) was used to observe changes in alpha-helical content (far-UV) 
and local environments surrounding aromatic residues (near-UV) in CaM when interacting with 
antagonists both in the presence and absence of NOS peptides. Spectra were fitted using BestSel 
CD analysis.92,93 Secondary structural elements were derived from the DSSP algorithm. 
 Stock Concentration Mix 
Concentration  
Volume of Stock for 1 Well 
(µL) 
Final Concentration in Reaction 
Well 
nNOS^ 1314 µM 0.025 µM 0.00761 0.030 µM 
FAD^ 1507 µM 8.33 µM 0.222 1 µM 
FMN^ 1307 µM 8.33 µM 0.254 1 µM 
H4B^ 6400 µM 41.66 µM 0.260 5 µM 
DTT^ 20000 µM 8.33 µM 0.0166 1 µM 
NADPH* 10000 µM 750 µM 3.00 450 µM 
BSA* 100 mg/mL 0.33 mg/mL 0.132 0.2 mg/mL 
Catalase* 89700 U/mL 83.33 U/mL 0.0372 50 µM 
SOD* 3100 U/mL 166.67 U/mL 2.16 100 U/mL 
Tris-HCl pH 7.5 50 mM 50 mM Fill to 40 µL total volume 50 mM 
Glycerol 20% 1.67% 3.34 1% 
Table 2.4 Enzyme solution of substrate-initiated assays. 
 
^Dilution factor of 0.12 to account for dilution upon mixing with and substrate solution and nNOS-inhibitor mixture. 
*Dilution factor of 0.6 to account for the dilution form the nNOS-inhibitor mixture. 
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Available reference sets are based on x-ray structures, resulting in reduced accuracy in the 
analysis of disordered or PII structure as these reference sets are not available.94 CaM is highly 
structured with no PII structure and the estimation of a-helical content is considered to be 
reliable. 
CaM-antagonist binding was first analyzed using far-UV CD, with antagonists being 
titrated up to 20 equivalents in relation to CaM in the presence of Ca2+ (1 mM). The raw spectra 
can be seen in Figure 2.2. Above 20 equivalents and high tension (HT) values approach the limit 
at which point the detector becomes saturated. The baseline spectrum with only CaM present 
displayed the characteristic double minima at 208 nm and 222nm associated with canonical 
alpha-helical secondary structure. Ellipticity at 222 nm is considered as a reasonable metric for 
percent helicity of protein structures.95,96 The ratio of bands at 208 nm an 222 nm is often used 
an additional metric of a-helicity however the effect of protein sequence on this ratio remain ill-
defined.97 TFP, a known potent CaM antagonist, was used as a positive control against which to 
compare structural rearrangements of CaM induced by aMT and AMK. The titration of TFP 
resulted in reduced molar ellipticity at both minima. The magnitude of this change is linear in 
relation to equivalents of TFP added until approximately 7 equivalents, at which point it begins 
to plateau until no further change in molar ellipticity is observed after approximately 10 
equivalents added (Figure 2.3A). BestSel secondary structure analysis estimated a drop in a-
helical content from 62.9% to 44% (Figure 2.4A). Similarly, AMK notably reduced intensity CD 
signal with the magnitude of change gradually reducing after approximately 10 equivalents 
(Figure 2.3B). This reduction corresponded to a drop in a-helicity from 64.7% to 44.9% (Figure 
2.4B). The titration of aMT resulted in minimal changes in signal at lower concentrations, with 
larger changes produced at higher concentrations (Figure 2.3C) although the signal appears 
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highly distorted at elevated amounts of the ligand (Figure 2.2C). 20-fold excess corresponded to 
an absurdly low 14.3% a-helical content (Figure 2.4C), thus the significance of these findings is 
moot. Indeed, previous CD studies involving CaM and aMT showed a similar loss in CD signal 
but suggested it may be the result of optical activity of aMT in the UV range.73 This was 
postulated as this behaviour was also seen in a titration where CaM was replaced by BSA.  
Although little can be drawn from the results of the aMT titrations, the titration data for 
AMK and TFP portray the characteristic shape of a saturable binding (Figure 2.3). The 
overarching trajectory of the curves can provide empirical information regarding the strength of 
interaction. TFP appears to saturate CaM as total concentrations of the ligand approach 10 molar 
equivalents, indicating a relatively strong interaction. AMK, conversely, does not saturate CaM 
but the magnitude of change tapers off gradually as ligand concentration increases, suggesting a 









Figure 2.2 Far-UV CD CaM-antagonist titration. 
CD Titrations acquired from 260-200 nm for CaM and increasing concentrations of (A) TFP, 
(B) AMK and (C) aMT (dark blue = 12 µM CaM, green = 12 µM CaM + 5x antagonist, red 12 
µM CaM + 10x antagonist, light blue = 12 µM CaM + 20x antagonist). Spectra were processed 










































Figure 2.3 Far-UV CD CaM-antagonist titration curves. 
Changes in CD signal at 208 nm (orange) and 222 nm (blue) from titrations acquired from 























































































Figure 2.4 Changes in a-helical content predicted by BestSel. 
Changes in secondary structure according to BestSel predictions are shown over the course of 





Far-UV circular dichroism was also used to characterize interactions between CaM and 
the CaM-binding domain peptides of NOS isoforms, known to bind with 1:1 stoichiometry, at 
saturated levels of Ca2+ both in the presence and absence of the antagonists. The NOS peptides 
are unstructured in solution, however upon binding to CaM they adopt an a-helical conformation 
resulting in increased CD signal.98 CaM was incubated for 20 minutes at room temperature with 
the antagonists at a 7-fold excess before the NOS peptide was added. The magnitude of change 
in molar ellipticity was compared to the control with no antagonist present. The addition of TFP 
yielded significantly smaller increases in signal when the nNOS peptide was added, however the 
increases were approximately equal to the control in the cases of eNOS and iNOS (Figure 2.5A). 
This suggests a TFP-mediated disruption of CaM-nNOS complex formation, which is in 
accordance with TFP’s documented capacity for isoform-specific reduction in nNOS 
activity.58,59,56,99 AMK generated a spectral profile similar to TFP, appearing only to impact 
CaM-nNOS formation and no significant changes observed with other isoforms (Figure 2.5B). 
This is in agreement with the purported specificity from studies involving AMK and is 
suggestive of previously posited mechanisms involving AMK-mediated structural change 
impacting the CaM-nNOS complex.61–63 The presence of aMT produced non-specific reduction 
in molar ellipticity change, however the magnitude of these differences was significantly smaller 








Figure 2.5 Antagonist-induced changes in subtractive Far-UV CD analyses of CaM and 
peptide-bound CaM. 
CD spectra of peptide-bound CaM subtracted by CaM alone with (green) and without (blue) 
(A) TFP, (B) AMK and (C) aMT. For each antagonist, the top panel corresponds to nNOS, the 
second to eNOS and the third to iNOS. Spectra were processed using the JASCO Spectra 
Manager Suite.  
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Key to understanding the mechanism responsible for AMK’s specificity is its interaction 
with each NOS isoform. The effect of AMK on the secondary structure of the NOS peptides was 
investigated using trifluoroethanol (TFE), which mimics hydrophobic environments and is 
known to induce a-helical conformation in peptides with a propensity to adopt this 
conformation. No structure for the peptide of any isoform was seen in buffer solution with 0% 
TFE. The a-helical content of the peptide was compared by recording spectra with increasing 
concentrations of TFE, which yielded increasingly negative minima at 208 nm and 222 nm. 
Negative ellipticity plateaued at 40% after which point any further change was negligible. AMK 
showed no significant impact on the induced helicity the NOS peptides, regardless of isoform. 
This would indicate that specificity is not the result of isoform-dependant rearrangement of 
secondary structure of the peptide prior to CaM binding. 
 
2.3.2 Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) was used to analyze the thermodynamic profiles 
of the interactions between AMK, CaM and NOS peptides. Since the values obtained for binding 
constants show slight variations when performed using different methods and conditions, all of 
our experiments were performed by ITC using exactly the same conditions.100,101 HEPES buffer 
was used to reduce background associated with (de)protonation heat effects. 
 Initial experiments attempted to characterize molecular recognition of AMK by CaM, 
with the peptide excluded from the system (Figure 2.6). In the presence of Ca2+ (1 mM), AMK 
binds to CaM by an exothermic interaction, and proceeds with a negative enthalpy (DH) and a 
positive entropy (DS). This demonstrates the reaction occurs with favourable enthalpy and 
entropy, corresponding to hydrophobicity and Van der Waals components of association. 
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Smaller endothermic peaks trail the exothermic ones following each injection, suggesting 
association followed by rapid dissociation. Binding proceeded with extremely low affinity 
indicated by the failure to produce a viable isotherm to generate binding parameters even at high 
concentrations of AMK (2 mM). This indicates the strength of the interaction is too weak and 
beyond the experimental limit of detection. Given the probability of CaM-AMK complexation 
occurring with a Kd > 1mM, it is unlikely conventional ITC experiments are capable of directly 
quantifying the interaction. This data is in agreement with the weakly associating behaviour 




Figure 2.6 Results from CaM-AMK ITC experiments. 
Raw data (top panel) and processed heats of injection (bottom panel) from 2 mM AMK into 10 µM 
CaM. A viable isotherm was not produced. 
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ITC was used to analyze the putative low affinity binding between CaM and AMK, 
making use of a method introduced by Zhang and Zhang for deriving low-affinity binding 
parameters based on curve fitting using a one-site model.102,103. The binding constant for the low 
affinity ligand is determined using the equation Kb = ([Ka / Kapp] – 1) x (1 / [B]t) where KA and 
KB are the binding constants for the high affinity and low affinity ligand (NOS and AMK 
respectively). Kapp is the experimentally measured binding constant, and [B]t is the ligand 
concentration.  
Complexation of CaM and NOS peptides was first conducted with no AMK present, and 
affinities were determined to be very similar to previously reported values.41 Particular emphasis 
was given to CaM-eNOS and CaM-nNOS, as the Ca2+-independent binding of iNOS likely 
circumvents purported the Ca2+-dependant inhibition from AMK. Both eNOS and nNOS bound 
to CaM in an exothermic manner in the presence of Ca2+ (1 mM), with negative DH and positive 
DS. Both peptides showed a 1:1 binding stoichiometry as expected. The presence of 100-fold 
excess AMK resulted in a modified CaM-nNOS isotherm (Figure 2.7A,B). This isotherm 
possessed initial endothermic peaks, representing a ~3.9 kcal/mol increase in DH relative to the 
AMK-free titration. As the peptide and CaM neared 1:1 stoichiometry these peaks disappeared, 
and the second half of isotherm reverted to one resembling baseline CaM-nNOS association as 
AMK is displaced by the peptide. Peptide into AMK control experiments produced consistent 
endothermic heats of injection with a DH value of ~3.4 kcal/mol, although no saturation was 
achieved (Figure 2.8). This would indicate the possible existence of a weak interaction between 
nNOS and AMK and rationalize the previously discussed change in isotherm. Initial endothermic 
peaks are potentially the result of two events: nNOS peptide interacting with excess AMK, and 
AMK being ejected from CaM as CaM binds to nNOS. At the inflection point where 1:1 
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stoichiometry is observed, AMK is completely ejected. eNOS into AMK control experiments 
produced endothermic peaks, albeit of a much smaller magnitude (DH  @ 0.9 kcal/mol)      
relative to its neuronal counterpart. Due to the apparent complexity of the systems, the 
competition model is not applicable as it assumes no interaction between high and low affinity 
targets.  
 Figure 2.7 Representative curves of CaM, nNOS and eNOS peptides with and without AMK. 
(A) 250 µM nNOS peptide into 25 µM CaM, (B) 250 µM nNOS peptide into 25 µM CaM pre-
incubated with 100-fold excess AMK, (C) 250 µM eNOS peptide into 25 µM CaM and (D) 250 
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Not only were competition assays unable to show a direct AMK-mediated impact on 
CaM-NOS complexation, they were also unable to indirectly quantify the strength of CaM 
binding to AMK. In an attempt to successfully accomplish the latter, a lower affinity peptide 
with no observed heats of association with AMK was used in hopes that any impact had from the 
antagonist would become apparent. Rat NSCaTE (rNSCaTE) peptide, a lower-affinity and Ca2+-
sensitive binding site for CaM in L-type Ca2+ channels, was selected and titrations were 
conducted as previously described for the NOS peptides.104 rNSCaTE into AMK control 
produced little to no signal, as did all CaM, AMK, and peptide to buffer experiments. 
Interestingly, competition assays showed increased affinity between CaM and rNSCaTE with 
AMK present 
Figure 2.8 Results from AMK-nNOS and AMK-eNOS ITC experiments. 
250 µM nNOS peptide into 2.5 mM AMK (black) and 250 µM eNOS peptide into 2.5 mM 
AMK (green). Molar ratio corresponds to the ratio between injected peptide and the CaM 







(Kd @ 4.2E6 M) than experiments absent AMK (Kd @ 9.1E6 M) (Figure 2.9). DS was 
determined to be slightly lower without AMK and DH was unchanged. It is possible that the 
antagonist induces a conformational change in rNSCaTE that renders it more suitable for CaM 
binding. ITC competition assays are typically conducted with a model assuming a reduction in 
affinity will be observed, as such it remains unclear as to whether binding parameters can be 
indirectly determined in instances where the opposite in reported.  
 
2.3.3 Gel Mobility Assays 
 Band shift assays on non-denaturing urea gels were used to further analyze CaM-nNOS 
peptide complex formation in the presence of the antagonists. The extremely consistent results, 
despite change in experimental design, are epitomized in Figure 2.10. High affinity between 
Figure 2.9 Representative ITC results from CaM and rNSCaTE peptides with and 
without AMK. 
(A) 500 µM rNSCaTE peptide into 25 µM CaM and (B) 500 µM rNSCaTE peptide into 25 µM 
CaM pre-incubated with 100-fold excess AMK. 
CaM_rNSCaTE 
N       1.401 
Ka      4.214E6 
DH   -4643 
DS     14.70 
CaM_rNSCaTE_AMK 
N       1.450 
Ka      9.073E6 
DH   -4595 
DS     15.584 
A B 
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CaM and the peptide is easily detectable using this method, manifesting in large changes in band 
mobility relative to unbound CaM. In the presence of Ca2+, the electrophoretic mobility of CaM 
was significantly reduced by the 1:1 addition of the nNOS peptide. Pre-incubation of CaM with a 
stoichiometric amount of TFP prior to loading with nNOS produced two bands: one with similar 
mobility to the CaM:nNOS complex and a weaker band with similar mobility to unbound CaM. 
This indicates that TFP binds to CaM in such a manner that it reduces the concentration of CaM 
available for complex formation with the peptide. Similar bands do not appear when CaM is pre-
incubated with aMT or AMK, indicating that any competition is considerably weaker. In assays 
conducted with no peptide present, the relative mobility of unbound holo-CaM was not altered 
appreciably by any of the antagonists regardless of urea concentration, suggesting their minimal 
impact on overall shape or charge. Gels with lower urea concentrations and native-state gels 
produced identical results. 4M urea and native gel mobility assays were also conducted with 
significantly higher concentrations of antagonists in an attempt to find the threshold 




Figure 2.10 4 M Urea-PAGE gel at with 1000-fold excess antagonist concentrations.  
CaM (lane 1), CaM + aMT (lane 2), CaM + nNOS peptide (lane 3), CaM + aMT + nNOS peptide 
(lane 4), CaM (lane 5), CaM + AMK (lane 6), CaM + nNOS peptide (lane 7), CaM + AMK + 
nNOS peptide (lane 8), CaM (lane 9), CaM + TFP (lane 10), CaM + nNOS peptide (lane 11), and 




CaM samples loaded with up to 1000-fold excess aMT and AMK (Figure 2.10) showed no 
changes in electrophoretic mobility and no residual unbound CaM bands were seen when the 
peptide was present. This stands in contrast to previous gel mobility studies with aMT and CaM 
in which residual CaM bands were observed at as low as 10-fold excess aMT, however myosin 
light-chain kinase (MLCK) was used as opposed to nNOS.73 Additionally, Camacho et al. 
showed significant changes in the electrophoretic mobility of unbound holo-CaM in the presence 
of 1 mM aMT and synthetic analogues similar to AMK, but the CaM concentration was not 
defined.63 Our negative results do not explicitly eliminate the possibility of binding competition, 
particularly due to the highly qualitative nature of gel data analysis but do support the likelihood 
of low CaM-AMK affinity.  
 
2.3.4 Enzyme Kinetics and SPR Studies 
The reduction of metHb yielded 5.90 % deoxyHb, 23.94 % and 70.16 % oxyHb, which is 
in agreement with expected values from previous studies.91 Calibration curves of metHb and 
oxyHb displayed the predicted linear relationship between absorbance and concentration. The 
difference in slopes was used to calculate OD401, which was determined to be 0.111 OD401 / nM. 
Enzyme-initiated OxyHb capture assays were conducted first, where CaM was incubated 
with AMK prior to initiating the reaction. AMK ranging from 33- to 1000-fold excess of nNOS 
did not appear to significantly influence enzyme activity, with small differences in activity 
falling within the margins of standard error (Figure 2.11A). These small changes are also not 
proportional with respect to concentration of AMK, further reducing the likelihood that the 
antagonist is the cause of the variances. In contrast, TFP in 1000-fold excess of nNOS greatly 
reduced Vmax values, particularly at lower concentrations of CaM. Substrate-initiated assays 
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where nNOS was incubated with AMK were carried out to further assess if direct AMK-nNOS 
complexation is involved in isoform-selective inhibition. L-NG-nitroarginine (LNNA) was used 
as a positive control for inhibition in this instance as it directly binds to nNOS as opposed to 
antagonizing CaM (Figure 2.11B). Despite the change in preparation, AMK did not produce 
observable differences in nNOS activity. Vmax values at each CaM concentration were extremely 








Figure 2.11 Oxyhemoglobin capture assays. 
(A) Enzyme-initiated assays using TFP as a positive control and (B) substrate-initiated assays 
using LNNA as a positive control carried out at increasing concentrations of CaM ranging 





 The lack of apparent AMK-induced enzyme activity inhibition contrasts a previous in 
vitro enzyme kinetics study using homogenates of rat striatum.62 Their findings suggested 
unambiguous, Ca2+- and dose-dependent inhibition of nNOS by AMK. These differences are 
likely the result of variances in sample sources and experimental protocols. Most kinetics studies 
that have successfully shown AMK- or aMT-mediated inhibition use biological nNOS samples 
and follow a previously described method which monitors the conversion of L-arginine to L-
citrulline using a biological source of nNOS as opposed to a purified source.105 This biological 
source is typically a striatal rat brain homogenate. Again we see differences in behaviour 
between biological and purified samples, as has been reported in the case of CaM-aMT 
binding.106 The few assays that show inhibition of a purified enzyme are carried out under lower 
Ca2+ concentrations, typically around 17.5 µM.105 Our results, therefore, do not discard the 
possibility of AMK-mediated inhibition but instead point to the potential importance of other 
factors not accounted for within the simplified system of the oxyHb capture assay.  
 Additional analyzation of binding kinetics under more physiologically relevant 
conditions could be of significant value. In addition to using biological samples as previously 
described, perhaps the most impactful modification would be to reduce Ca2+ to concentrations 
similar to elevated free Ca2+ values in the body, or approximately 225 nM.107 In studies where 
CaM exists in a partially Ca2+-replete state, overall affinity for the CaM-binding domain peptide 
of NOS is reduced. The C-terminal domain, which has a 10-fold higher affinity for Ca2+ 
compared to the N-terminal domain, saturates first and binds to NOS. The Ca2+-deplete N-
terminal domain largely retains its apo-CaM conformation and thus hydrophobic cavities within 
are not exposed, resulting in a much weaker association with the NOS peptide.107,108 This 
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deteriorated binding strength could potentially facilitate CaM antagonism from compounds such 
as AMK and help elucidate the significant effects seen in previous studies.61–63  
 SPR displacement assays revealed a subtle effect of AMK on CaM-NOS complexation. 
Spectra were first obtained with no antagonist present to evaluate binding kinetics of CaM with 
the NOS peptides. The experimentally determined ka values for eNOS and nNOS were highly 
analogous to literature values (Table 2.5). kd and Kd constant were also reasonably comparable 
although both were higher than expected values.  
 
 
Displacement assays were carried out by pre-incubating CaM with AMK at varying 
concentrations prior to injection and comparing binding parameter to baseline experiments 
(Figure 2.13). In nNOS peptide displacement assays, 1000-fold excess AMK produced minimal 
effects on the equilibrium dissociation constant (Kd @ 49.6 nM), whereas 10000-fold excess 
appeared to produce a notable increase (Kd @  206.3 nM). In comparison, eNOS displacement 
assays at 10000-fold excess AMK had no impact on binding to CaM (Kd @  15.3 nM). These 
results, although subtle, may suggest a structural basis for the purported isoform-dependent 
inhibitory characteristics of AMK, however further investigation is required. 
  
 ka (M-1 s-1) x 105 kd (s-1) x 10-4 Kd (M) x 10 -9 
nNOS109 1.58 7.9 5.0 
eNOS107 1.31 ± 0.48 3.5 ± 1.0 2.7 ± 0.2 
nNOS 1.90 ± 0.13 30.1 ± 0.15 18.8 ± 0.32 
eNOS 2.17 ± 0.001 26.2 ± 0.02 11.7 ± 0.02 






Figure 2.12 ITC competition assays with nNOS and eNOS peptides. 
Comparison of (A) ka, (B) kd and (C) Kd values for CaM binding to nNOS and eNOS peptides 
with increasing AMK concentrations. nNOS data is shown in blue and eNOS in orange. Trends 








 We set out to understand the effects of aMT and AMK, with particular focus on the latter, 
on complexation between CaM and NOS isoforms. Previous studies reported both compounds 
were able to inhibit NOS activity in vivo and in vitro, with experimental evidence suggesting this 
is accomplished through antagonizing CaM.110,111,63,61 Various other biophysical analyses have 
been carried out involving CaM and aMT and indicate a weak interaction between the two 
compounds.73,74 The present study build upon previous work and provides hitherto unknown 
information regarding the interaction between CaM and AMK. Although the titration of AMK in 
far-UV CD experiments produced changes in the CD signal for CaM, saturation was not 
achieved. Similarly, gel mobility assays involving AMK far in excess of CaM did not produce 
any observable deviation in electrophoretic mobility. Direct assessment of CaM-AMK binding 
using ITC was unsuccessful, as saturation was not possible within the reasonable bounds of 
experimental design. These results strongly suggest a similarly weak interaction (likely Kd > 1 
mM) between CaM and AMK as previously reported in the case of aMT.73,74 
 The impact of AMK on CaM complexation with the CaM-binding domain peptides of 
NOS and nNOS enzyme activity were similarly subtle. Although affinities between CaM and 
NOS peptides appeared unaltered by AMK, respective isotherms for eNOS and nNOS peptides 
were modified by the presence of the antagonist but the nature of the interaction remains unclear. 
SPR competition assays did show a potential loss in binding affinity in the case of nNOS, but 
only at extremely high concentrations of AMK. SPR assays also showed a potential isoform-
dependant impact, with eNOS binding remaining unaffected at the same high antagonist 
concentrations. Although the capacity for potent competition is doubtable, the purported 
isoform-specific effects are promising. This specificity was further reflected far-UV CD 
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experiments in which the increase in secondary structure seen when the nNOS peptide binds to 
CaM was reduced when AMK was present, but not in the case of other isoforms. Although 
nNOS enzyme activity was unaffected in oxyHb capture assays, this does not necessarily negate 
the capacity of AMK to act as a CaM antagonist. Instead, it is perhaps reflective of a need for 
more biologically relevant conditions, such as physiological Ca2+ concentrations or the use of a 
















Chapter 3  




The use of structure-based analysis of protein-ligand interactions has proved highly 
invaluable, particularly in field of drug design.112 Nuclear magnetic resonance spectroscopy 
(NMR) is amongst the most useful tools in this respect, allowing precise detailing of many 
biomolecular complexes and is well-suited to ascertain an understanding of the interaction 
between CaM and AMK.  
Although several studies have documented the capability of AMK inhibit nNOS via 
antagonizing CaM, there is little in the way of a structural explanation of how this manifests on a 
molecular scale.61–63 In characterizing the binding between AMK and CaM, it becomes possible 
to discern the means by which this antagonism is accomplished. To this end, NOE-based 
techniques using 2D and 3D NMR experiments can be highly effective and can produce high 
resolution structures of protein-ligand complexes. The caveat is that intermolecular NOEs are not 
always visible, particularly for weak interactions and thus alternate NMR techniques such as 
chemical shift monitoring can be used in parallel. Indeed, a previous study investigating the 
complexation of aMT and CaM found that no such NOEs were observed due to the millimolar 
range residue-specific Kd values.74 Here we present a comprehensive structural analysis of the 
CaM-AMK complex using NMR, combining 2D NMR 15N-HSQC titrations with 3D structure 
determination of CaM from NOE distance constraints. In this way, changes in the conformation 
of CaM when bound to AMK and the probable location of binding surfaces were elucidated.  
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3.2 Methods and Experiments 
3.2.1 Expression and Purification of Isotopically labelled CaM 
An overnight culture of transformed E. coli BL21 (DE3) with pET9dCaM was used to 
inoculate 1 L of M9 media (11.03 g/L Na2HPO4·7H2O, 3.0 g/L KH2PO4, 0.5 g/L NaCl, 2 mM 
MgSO4, 0.1 mM CaCl2, 3 μM (NH4)6(MO7)24, 400 μM H3BO3, 30 μM CoCl2, 10 μM CuSO4, 80 
μM MnCl2·4H2O, 10 μM ZnCl2, 10 mM FeSO4, 100 μg/mL kanamycin) containing 2 g/L 13C-
glucose and 1 g/L 15NH4Cl. 15N-13C-CaM was purified as previously described in Chapter 2. 
The samples were prepared for NMR experiments via a buffer exchange into NMR solution (100 
mM KCl, 10 mM CaCl2, 0.2 mM NaN3, 90% H2O/10% 2H2O) at pH 6.0 using a YM10 
centrifugal filter device (Millipore Corp., Billerica, USA). All NMR samples contained at least 
350 µM CaM in a total volume of 500 μL. The samples were transferred into 5 mm NMR sample 
tubes and stored at 4°C until required for NMR experiments.  
 
3.2.2 NMR Spectroscopy Data Acquisition and Analysis 
NMR spectra were recorded at 25°C on a Bruker 600 MHz DRX spectrometer equipped 
with XYZ gradients triple-resonance HCN probe (Bruker, Billerica, MA, USA). Spectra were 
analyzed using the Computer Aided Resonance Assignment (CARA) program.113  
Specific assignments of the CaM backbone resonances were achieved using a 
combination of 2D HSQC and 3D triple resonance experiments including HNCA, 
CBCA(CO)NH, HN(CO)CA, and HNCO.114,115 Side-chain resonances were assigned using 
various TOCSY type experiments; HC(C)H-TOCSY, (H)CCH-TOCSY and H(CCO)NH.116 
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3.2.3 15N-HSQC NMR Titration  
15N-HSQC spectra were acquired with AMK being titrated into samples containing 350 
μM CaM at pH 7.3. Spectra were recorded at 1-2 equivalent intervals until an AMK:CaM ratio 
of 7:1 was achieved. Changes in pH caused by the addition of AMK were accounted for by the 
titration of 0.1 M NaOH.  
The changes in chemical shifts of individual nuclei resonances were fitted using the 
standard non-linear least-squares method. Kd values were determined using the equation Ddobs = 
Ddmax {([P]t + [L]t + Kd) – [([P]t + [L]t + Kd)2 – 4[P]t[L]t1/2}/2[P]t where [P]t, [L]t, Ddobs and 
Ddmax are total protein concentration, total ligand concentration observed change from the free 
state and the maximum shift change upon saturation respectively.  
 
3.2.4 Structure Calculations of the CaM-AMK Complex 
The 1H, 13C and 15N resonance assignments were used to identify constraints for structure 
calculations. Distance constraints for the solution structure of CaM-AMK were obtained from 
3D 15N-NOESY-HSQC and 13C- NOESY-HSQC spectra. Intramolecular NOEs of the ligand and 
intermolecular NOEs were analyzed with 15N-double-filtered NOESY and 15N/13C-edited 
double-filtered NOESY spectra acquired on samples containing labeled CaM and unlabeled 
AMK.117–119 In addition, dihedral angle restraints were derived from chemical shift analysis with 
TALOS+.120. CNSsolve version 1.2 was used for structure determination and refinement.121 
Calculations were initiated with an extended conformation file and run through several iterations 
of a standard simulated annealing protocol in order to minimize the energies. The 20 lowest-
energy structures were generated and averaged. 
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3.3 Results and Discussion 
3.3.1 3D CaM-AMK Complex Structure Calculations. 
 The NMR analysis of CaM complexation with 7 molar equivalents of AMK in the sample 
was conducted according to routine procedures with backbone resonance assignment (Figure 
3.1A) based on 3D triple resonance techniques. Although spectral changes in fast exchange on 
the NMR timescale brought on by AMK were observed, these changes were small enough that 
previously assigned chemical shifts of wildtype holo-CaM could be used as a starting point. The 
HNCA experiment (Figure 3.1B) was used in conjunction with CBCA(CO)NH and HN(CO)CA 
experiments. Collectively, these techniques allowed for the complete backbone assignments for 
the CaM-AMK complex, with the exception of prolines. Sidechain resonances for CaM were 
determined using HC(C)H-TOCSY, (H)CCH-TOCSY and H(CCO)NH experiments. 15N-
double-filtered NOESY and 15N/13C-edited double-filtered NOESY in an attempt to assign 




















































Figure 3.1 Composite figure of NMR structural data. 
(A) 15N-HSQC spectrum of the CaM structure when bound to AMK. (B) 3D 
HNCA strips of sequential amino acids K21 to D24. The connection between 
alpha carbons are shown. 
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No intermolecular NOE effects were observed between AMK and CaM, similar to results 
seen in NMR experiments involving CaM and aMT.74 The absence of these NOEs is likely the 
result of the very weak interaction, and as a result determining the precise contact formation 
involved in binding becomes infeasible. 3D structure determination is still valuable in this 
instance, however, as it can elucidate the conformational changes in CaM upon forming a 
complex with AMK. CNSsolve was used in accordance with experimentally determined NOE 
constraints and dihedral angle constraints from TALOS+.  
 Solution structures of CaM when bound to AMK are extremely similar to the unbound 
form of holo-CaM, suggesting that AMK has a minimal impact on structure. No long-range 
NOEs were observed between helices of opposing globular domains, which characterize a 
typical bound conformation. Superposition of the lowest energy structures (Figure 3.2A) also 
shows the mobile nature of the linker region, which is typical of holo-CaM in solution. The N- 
and C-terminal domains retain their conformational independence, remaining largely separated 
by the central helix and linker region (Figure 2.2B). This contrasts X-ray crystallography studies 
involving CaM and TFP, in which the antagonist was shown to cause significant conformational 
change in CaM.58,59 In this instance, TFP appears to induce significant bending of the flexible 
central linker region in addition to small changes in the N- and C-terminal domains. The 
difference seen between these two compounds is perhaps reflective of the stark contrast in their 
respective affinities (Kd = 10 µM vs. Kd > 1 mM for TFP and AMK respectively), however a 
similarly unchanged overall conformation is seen with antagonists such as W-7, which binds to 
CaM with the same affinity as TFP.122,123 The 2:1 W-7-CaM solution structures display relative 
mobility of the globular domains, with one ligand per domain buried in the hydrophobic cavities. 
As structures involving TFP have broadly been carried out using X-ray diffraction, complexation 
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with W-7 using solution-state NMR is perhaps a more translatable comparison. Our findings are 
also congruous with those from measurements of interdomain NMR pseudocontact shifts and 
residual dipolar couplings induced my magnetic alignment in CaM bound to aMT where Ca2+ 
was partially replaced by paramagnetic Terbium (Tb3+).74 It was shown that the CaM-aMT 
complex also behaves as uncomplexed CaM, with the globular domain possessing orientational 
freedom from one another.74  




Figure 3.2 Structures of CaM when in complex with AMK. 
(A) Backbone view of the superposition of the 10 lowest energy structures of CaM when 
bound to AMK. (B) Ribbon view of a the most likely structure of CaM when in complex with 
AMK coloured according to secondary structure. a-helices are shown in red, β-sheets in blue 





3.3.2 15N-HSQC NMR Titration  
 
NMR spectroscopy was used to assess residue-specific changes in CaM structure upon 
binding to AMK. Increasing concentrations of AMK up to a 7-fold excess were titrated into 350 
µM CaM and 15N-HSQC spectra were acquired after each titration. Changes in structure were 
determined by monitoring changes in chemical shifts specific to each residue in CaM. NMR 
spectral changes for 15N- 13C-labelled CaM occurred in fast exchange on the NMR timescale, 
which produced signals with averaged chemical shifts for a given nucleus, rapidly exchanging 
between bound and unbound states. This indicates a weak interaction, in which koff values are 
larger than the chemical shift difference between the free and bound form of the protein. As a 
result, the CaM-AMK complex is only stable for a short period of time. The superposition of 
15N-HSQC spectra at various molar ratios of CaM and AMK are shown in Figure 3.3A, which 
displays the gradual shift of NH peaks over the course of the titration.   
 Perturbation of 1H and 15N chemical shifts were normalized using the function 
Ddnorm=Ö((DdH)2+(DdN x 0.2)2), and the magnitude of these normalized values for each residue 
can be seen in Figure 3.3B. A threshold of 0.03 ppm was used in determining residues displaying 
significant changes in chemical shifts brought on by the titration of AMK. Approximately 28% 
of residues in CaM surpassed threshold values, similar to the 22% of residues showing 
significant change in another study with a 15N-HSQC titration involving aMT and CaM, 
although their criteria for a significant change is not clearly stated.74 A comparison of the two 
titrations reveals similarities in the impact on structure of AMK and aMT, with the majority of  
significant changes being localized to the hydrophobic pockets in globular domains of CaM. 
Many of the most affected residues are also those shown to interact most strongly with the 





Figure 3.3 15N-HSQC titration spectral overlay and chemical shift changes. 
(A) 15N-HSQC spectra over the course of titration ranging from 0 equivalents (red) to 7 
equivalents (blue) of AMK. (B) Normalized magnitudes of chemical shift perturbations. The 
largest changes were localized to the hydrophobic cavities of CaM. 
B 
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61 % of  large shift changes were observed in the C-terminal domain, although N-terminal shifts 
changes were notably larger in magnitude. The collective perturbations are widespread 
throughout the entirety of the sequence, suggesting that AMK likely scavenges the surface of the 
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Figure 3.4 15N-HSQC titration curves of residues with largest chemical shift changes.  
15N-HSQC titration curves for the residues exhibiting the largest changes in the (A) N- and (B) 
C-terminal domains. (C) Location of the representative residues within the solution structure of 
CaM when bound to AMK. CaM backbone and sidechains are shown in beige, sulfur in 

















Analysis of binding curves generated from the normalized changes in chemical shifts 
relative to the initial spectrum show no saturation is achieved (Figure 3.4), similar to what was 
seen in various biophysical analyses described in Chapter 2. A total of 8 residues exhibiting the 
largest unambiguous chemical shift perturbation from each globular domain were selected for 
non-linear least-squares fitting using a saturation/growth model to predict Kd values. Every 
representative residue displayed Kd values in the millimolar range, similar to other NMR 
titrations involving aMT.73,74 Independent fitting suggests that the N-terminal binds with similar, 
albeit marginally higher affinity than the C-terminal domain (Kd = 2.94 mM vs. 3.35 mM 
respectively) (Table 3.1, Table 3.2). These values denote a 2-4 mM decrease from those 
determined by Turjanksi et al, although this difference is potentially within the margins of error 

































L4 2.78 ±0.5 7.66 122.534 7.561 122.358 
F19 3.24 ±0.7 7.193 115.834 7.139 115.511 
V55 3.00 ±0.2 7.08 108.822 7.067 109.448 
A57 2.91 ±0.4 8.333 132.451 8.273 132.451 
E67 3.07 ±0.7 7.807 118.327 7.879 118.327 
L69 2.86 ±0.2 8.202 119.596 8.317 119.786 
T70 2.81 ±0.3 7.358 116.333 7.417 116.333 
R74 2.82 ±0.5 7.472 117.459 7.348 116.972 
Average 2.94 ±0.4 
*error values were determined by the fitting program for a given fit and do not necessarily 
reflect precise margins of error in Kd itself. 
 






15N-HSQC NMR experiments were also conducted to see whether AMK had an 
observable impact on the chemical shifts of CaM when bound to the CaM-binding domain 
peptide of nNOS. AMK was titrated into sample containing CaM until a 7:1 AMK:CaM ratio 
was achieved, and the spectrum was recorded. nNOS peptide was then titrated into the sample 
and spectra were recorded until no further changes in chemical shifts occurred. This was 
compared to a 15N-HSQC spectrum with no AMK present. Slow exchange on the NMR 
timescale was observed, consistent with the nanomolar range affinity between CaM and the 
peptide. The overlay of CaM-nNOS peptide 15N-HSQC spectra can be seen in Figure 3.5. 
Empirical analysis shows no change in backbone chemical shifts when CaM is first bound to 
AMK, indicating that the ligand is likely ejected from CaM when nNOS is present in 

























M109 2.94 ±0.6 8.095 117.33 8.136 117.179 
K115 4.82 ±0.4 8.435 124.418 8.449 124.638 
A128 4.69 ±0.3 7.222 119.633 7.199 119.426 
F141 2.90 ±0.5 8.859 125.586 8.801 125.445 
V142 2.86 ±0.5 8.38 120.131 8.431 120.131 
Q143 2.98 ±0.2 7.197 118.612 7.274 118.833 
M144 2.87 ±0.5 7.844 120.505 7.729 120.075 
M145 2.76 ±0.7 7.718 115.398 7.561 115.658 
Average 3.35 ±0.5 
Table 3.2 Estimation of C-terminal domain Kd from 1H and 15N chemical shifts 
 
*error values were determined by the fitting program for a given fit and do not necessarily 








 This is the first study to use multidimensional NMR to provide structural details of the 
interaction between CaM and AMK. No major changes in the overall architecture of CaM and 
the absence of intermolecular NOEs yet again points to a weak interaction. 15N-HSQC NMR 
titrations proved to be effective in providing the qualitative and quantitative analytical 
framework necessary for such a system. An approximate affinity was determined to be in the low 
millimolar range, as suggested by studies involving aMT, and the chemical shift perturbations 
show similar likely binding surfaces between the two compounds. The prevalence of these 
perturbations throughout the sequence of CaM suggests that AMK associates via transient 
Figure 3.5 Impact of AMK on the CaM-nNOS 15N-HSQC spectrum. 
15N-HSQC spectral overlay for CaM bound to nNOS in the absence (red) and presence (blue) 
of 7 molar equivalents of AMK. No changes in chemical shifts were observed. 
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contacts formed at several locations, although primarily within the exposed hydrophobic cavities 
of the protein. The overall conformation of CaM when bound to AMK and the likely binding 
surfaces indicate that AMK occupies similar sites as W-7. This information not only provides 
new insight into the potential mechanism of antagonism but validates certain NMR techniques as 












Chapter 4  




 While crystallographic and NMR studies are highly valuable in the study of protein-
ligand interactions, they face numerous restrictions that reduce their effectiveness. Aside from 
the detraction of being labour intensive, they are limited in their capacity for acquisition of 
structural information for weakly interacting systems.124 Such systems often do not crystallize or 
if so, not in a biologically relevant conformation. NMR methods using NOE constraints for 
assignment are equally often equally ineffective, with the widely accepted threshold for such a 
technique to work being approximately Kd = 10 µM.74 Computational techniques to predict 
protein binding offer an appealing alternative. Molecular dynamics (MD) simulations represent 
one such alternative, using simple Newtonian physics to approximate quantum mechanical 
motions and the biochemical reactions of large systems.125 
 Biophysical analyses and NMR work from the present study strongly suggests a very 
weak interaction between CaM and AMK (Kd > 1 mM) and thus computational techniques were 
used for a more considered examination of binding. Similar MD simulations with aMT, AMK’s 
structurally similar parent compound, and CaM have been conducted to good effect although the 
scope of the study was limited to only the C-terminal domain.74 Our study builds upon this work, 
using MD simulations to provide hitherto unknown information regarding interactions between 
CaM, AMK and the CaM-binding domain peptide of nNOS.  
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4.2 Methods and Experiments 
4.2.1 Molecular Docking Simulations 
 Predicted docking sites and orientations for AMK when in stable complex with CaM 
were determined using AutoDock Vina in parallel with AutoDock Tools.126 CaM and AMK 
structures (PDB 3CLN and PubChem CID 390658 respectively) were prepared in USCF 
Chimera with solvent removed to ensure accurate calculations.127 All hydrogens were added in 
AutoDock Tools and the entire protein was selected for docking analysis. AutoDockVina 
generated 20 of the most favourable poses according to a scoring function based on free energies 
of binding. The most favourable structures were selected for future use in MD simulations. The 
same protocol was used for docking simulations involving the nNOS peptide and AMK. Docking 
simulations involving AMK and the CaM-nNOS peptide complex were carried out using PDB 
2O60 for the complex. 
  
4.2.2 Molecular Dynamics Simulations 
 Visual Molecular Dynamics (VMD) was used to generate the protein structure files (PSF) 
with the Automatic PSF Builder plugin.128 The PSF files contain all of the molecule-specific 
information necessary for the application of the CHARMM force field to the molecular 
systems.84 All complexes were solvated in a cubic water box with an edge length of 80 Å using 
the Solvate plugin and ionized with 0.15 M CaCl2 with the Autoionize plugin. VMD was further 
used in the visualization of coordinate trajectories following simulations. Topology and 
parameter files for AMK in each pose were created using SwissParam.129 Biomolecular MD 
simulations were conducted using the Nanoscale Molecular Dynamics (NAMD) software 
package via the Graham computing cluster in association with Compute Canada.130  
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 The lowest energy poses of AMK bound to CaM from AutoDock Vina were used as 
initial coordinates for a 10 ns minimization and equilibration at 310 K. The extent to which the 
system had equilibrated was verified with RMSD before carrying out a 20 ns production run. 
Coordinates were recorded every picosecond and a 1 Å grid spacing was used. The same 
protocol was used for AMK-nNOS peptide and AMK-CaM-nNOS studies.  
 
4.3 Results and Discussion 
4.3.1 Molecular Docking Simulations  
 
4.3.1.1 CaM-AMK Docking Simulations 
 
 AutoDock Vina generated the 20 most favourable CaM-AMK poses according to 
docking scores based on free energy of binding (Table 4.1). Docking simulations were repeated 
three times to ensure consistent solutions. The scores for each respective pose ranged from -4.4 
kcal/mol to -3.5 kcal/mol. The seven most favourable poses were largely consistent, varying only 
by 0.2 kcal/mol. The spatial coordinates, however, varied greatly across all 20 models with best 
mode RMSD (upper bound) differing by as much as 47.472 Å from model 1. The 20 poses could 
be sorted into one of six different approximate docking sites (Figure 4.1). The distribution of 
models among the 6 sites are seen in Table 4.2. Four of the sites are located in the N-terminal 
domain and two in the C-terminal domain. At sites one and six, AMK is nestled in the 
hydrophobic cavity of the N- and C-terminal domains, proximal to the methionine 
residues that constitute nearly half of CaM’s hydrophobic surface area (Figure 4.2A,B).16 Sites 
two, three and five are characterized by hydrophobic contacts near the edge of the cavity and 
polar interactions with the hydrophilic, negatively charged glutamate and aspartate clusters 
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within in the globular domains (Figure 4.2C). These polar interactions are predominant at site 












MODEL AFFINITY (KCAL/MOL) DISTANCE FROM RMSD L.B BEST MODE RMSD U.B 
1 -4.4 0.000 0.000 
2 -4.3 12.862 14.620 
3 -4.3 36.213 37.771 
4 -4.3 35.359 37.191 
5 -4.2 15.025 16.369 
6 -4.2 37.438 39.151 
7 -4.2 3.442 4.942 
8 -4.1 37.361 38.952 
9 -4.1 46.284 47.961 
10 -4.0 35.963 37.701 
11 -4.0 38.271 39.771 
12 -4.0 45.778 47.472 
13 -3.9 19.211 21.271 
14 -3.9 15.398 16.729 
15 -3.7 13.680 15.011 
16 -3.7 16.037 17.742 
17 -3.7 19.565 21.611 
18 -3.6 15.062 16.376 
19 -3.6 19.345 21.225 
20 -3.5 18.681 20.562 
Figure 4.1 20 highest affinity docking poses of AMK bound to CaM generated by 
AutoDock Vina. 
(A) Proximal view of the N-terminal domain displaying docking sites 1 and 2. (B) Distal view 
on the N-terminal domain showing docking sites 3 and 4. (C) Proximal view of the C-terminal 
domain showing docking site 5. (D) The distal view of the C-terminal domain displaying 
docking site 6. CaM is shown in beige, Ca2+ ions as green spheres and polychromatic AMK 
molecules are shown with each colour corresponding to a unique pose. Figures were prepared 
using UCSF Chimera v. 1.13.1. 
A B 
Table 4.1 Scoring for 20 highest affinity AutoDock Vina-generated CaM-AMK models. 
 
Site 1 













4.3.1.2 AMK-nNOS Docking Simulations 
 
A similar docking procedure as described in the case of CaM-AMK complexation was 
carried out in order to further analyze any interactions that may occur between AMK and the 








































Figure 4.2 Hydrophobicity surface mapping of CaM near predicted AMK binding sites.  
Kyte-Doolittle hydrophobicity surface mapping of CaM near (A) model 5, (B) model 9, (C) 
model 1 and (D) model 2 poses. These correspond to binding sites 1, 6, 3 and 4 respectively. 
Blue corresponds to most hydrophobic and red to most hydrophilic. Figures were prepared 
using UCSF Chimera v. 1.13.1. 
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Figure 4.3. The affinities ranged from -5.1 kcal/mol to -3.7 kcal/mol (Table 4.3), and spatial 
coordinates of the poses were highly consistent. Two docking locations were identified for 
nNOS, with almost all of the more likely poses occurring with the phenyl moiety close to the 
hydrophobic residue F16 and polar contacts forming between AMK and E12. Model 1 (the most 














MODEL AFFINITY (KCAL/MOL) DITANCE FROM RMSD L.B BEST MODE RMSD U.B 
1 -5.1 0.000 0.000 
2 -4.9 1.848 12.479 
3 -4.8 2.602 12.681 
4 -4.5 2.244 5.756 
5 -4.5 2.818 11.681 
6 -4.4 2.282 12.787 
7 -4.4 2.684 11.448 
8 -4.4 2.739 3.964 
9 -4.3 2.416 6.464 
10 -4.3 9.629 14.024 
11 -4.2 3.332 13.885 
12 -4.1 1.774 14.860 
13 -4.1 2.546 12.501 
14 -4.0 1.853 3.562 
15 -4.0 9.945 11.410 
16 -3.9 9.943 6.324 
17 -3.9 9.481 12.733 
18 -3.8 9.610 11.602 
19 -3.8 2.734 11.815 
20 -3.7 3.654 12.717 
Table 4.3 Scoring for 20 highest affinity AutoDock Vina-generated nNOS-AMK models.  
 
A B 
Figure 4.3 20 highest affinity docking poses of AMK bound to the nNOS peptide 
generated by AutoDock Vina. 
(A) side view and (B) frontal view of the the 20 most favourable AMK poses with nNOS 
peptide. The peptide is shown in beige, oxygens in red, hydrogens in white, nitrogens in blue 
and polychromatic AMK molecules are shown with each colour corresponding to a unique 






4.3.1.3 AMK-CaM-nNOS Docking Simulations 
 
A final set of docking simulations were carried out to identify the likely docking sites of 
AMK on a CaM-nNOS peptide complex. Most of the 20 poses generated were localized at the 
point where the N- and C-terminals meet, having wrapped around the peptide (Figure 4.4). In 
this conformation, AMK is coordinated by hydrogen bonds with a cluster of lysine residues and a 
glutamate in the nNOS peptide. Proximal methionine residues (M72, M76, M145) in CaM 
contribute to hydrophobic coordination of AMK in this pose.  
 
   
MODEL AFFINITY (KCAL/MOL) DITANCE FROM RMSD L.B BEST MODE RMSD U.B 
1 -5.1 0.000 0.000 
2 -5.1 18.386 19.649 
3 -5.0 2.291 6.056 
4 -5.0 3.695 7.674 
5 -4.9 2.562 3.450 
6 -4.9 17.814 20.018 
7 -4.9 1.696 1.952 
8 -4.8 2.675 4.190 
9 -4.8 2.723 4.285 
10 -4.8 3.372 4.767 
11 -4.7 3.447 5.286 
12 -4.6 2.461 3.336 
13 -4.5 2.204 5.486 
14 -4.5 17.321 18.942 
15 -4.5 21.729 23.367 
16 -4.5 16.144 17.809 
17 -4,4 11.123 12.067 
18 -4.4 18.637 19.562 
19 -4.3 18.252 20.836 
20 -4.3 17.246 18.723 
Table 4.4 Scoring for 20 highest affinity AutoDock Vina-generated AMK-CaM-nNOS models.  
models. 
 
Figure 4.4 20 highest affinity docking poses of AMK bound to the CaM-nNOS peptide 
complex generated by AutoDock Vina. 
The 20 most favourable AMK poses with the CaM-nNOS peptide complex. The peptide is shown 
in red and CaM in beige with oxygens in red, hydrogens in white, nitrogens in blue and 
polychromatic AMK molecules are shown with each colour corresponding to a unique pose. The 
most favourable poses are typically found in the region circled in red. Figures were prepared 
using UCSF Chimera v. 1.13.1. 
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4.3.2 Molecular Dynamics Simulations 
4.3.2.1 Molecular Dynamics Simulations of CaM-AMK Complexation 
 Poses of AMK bound to CaM from AutoDock Vina were selected for NAMD 
simulations according to affinity scores and concurrence with 15N-HSQC NMR titration data 
described in Chapter 3. A 10 ns minimization and equilibration of the highest affinity CaM-
AMK pose (model 1) was conducted first and the RMSD of the backbone a-carbon atoms 
showed a reasonably equilibrated system (Figure 4.5A). The distance from the methoxy oxygen 
(O1) and the amine nitrogen (N2) from the phenyl moiety in AMK to the a-carbons of I63 and 
F19 of CaM was used as a geometrical parameter to structurally characterize the MD simulation 
(Figure 4.5B). These two residues were chosen as they straddle the approximate center point of 
the N-terminal hydrophobic cavity and their position changes very little over the course of the 
simulation.  
  
Figure 4.5 RMSD of CaM-AMK MD simulations and geometrical parameterization of 
trajectories.  
(A) RMSD of a 10 ns minimization and equilibration with model 1 used to generate starting 
coordinates. (B) The distances from O1 and N2 to F19 and I63 used to characterize simulations 
are shown in VMD.  
A B 
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 During the first 3.2 ns of equilibration, AMK begins migrating from its starting position 
near the loop segment of EF hand 1 on the outside of the hydrophobic cavity down towards L4. 
During this period, the antagonist shifts away from the bottom of the cavity by as much as 20 Å 
(Figure 4.6A). Following this, AMK appears to wedge between the helical segment of EF hand 1 
and the helical region preceding the flexible linker region (Figure 4.6B). AMK then gradually 
settles into the hydrophobic cavity where it stays for the remainder of the equilibration.  
  
Figure 4.6 Model 1 minimization and equilibrium MD trajectory. 
(A) The change in distance between Ca of I63 and O1 of AMK (black), Ca of F19 and O1 of 
AMK (red), Ca of F19 and N2 of AMK (green) and Ca of I63 and N2 of AMK (blue). (B) 
Progression of the 10 ns equilibration with the starting pose seen in the first panel, midpoint in the 
second panel and the final conformation in the third. CaM is shown in beige and AMK in cyan. 
Oxygens are shown in red, hydrogens in white and nitrogens in blue. Structures were prepared 
using UCSF Chimera v. 1.13.1. 
A 
B 
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Figure 4.7 Model 1 production MD trajectory. 
(A) The change in distance between Ca of I63 and O1 of AMK (black), Ca of F19 and O1 of 
AMK (red), Ca of F19 and N2 of AMK (green) and Ca of I63 and N2 of AMK (blue). (B) 
Progression of the 20 ns production simulation with the predominant conformation of the first 
part of the trajectory seen in the first panel, and the predominant conformation adopted in the 
latter portion of the simulation shown in the second panel. Structures were prepared using UCSF 
Chimera v. 1.13.1. 
0 ns 20 ns 
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During the 20 ns production simulation with periodic boundary conditions, AMK 
remained entirely within the N-terminal cavity throughout.  The initial orientation of AMK was 
maintained for the first 12.6 ns, after which it was rotated such that the phenyl moiety was 
angled more towards the central helical region (Figure 4.7B) The mobile nature of the interaction 
makes it difficult to provide a definitive model for association, but residue-specific trends are 
indeed observed (Figure 4.8). The first conformation during the simulation is characterized by 
loose, non-specific hydrophobic interactions between AMK and residues such as L32, V55, 
M36, M51 and M71. A consistent aromatic-aromatic contact is also seen between the phenyl 
moiety and F19. It also appears that as AMK moves closer to the central helix, the acetyl moiety 
of AMK interacts with K75 via a hydrogen bond. The second part of the simulation is 
characterized by the proximity of the hydrophobic cavity to the extended chain of AMK. A p-
cation interaction is fleetingly seen between K75 and the phenyl moiety. The nature of all of 







Figure 4.8 Model 1 protein-ligand contact analysis for CaM and AMK during the production 
MD simulation. 
The expected formation of hydrophobic (             ), electrostatic ( ------- ) and hydrogen bond  
( ------- ) contacts between CaM and AMK during the initial (A) and concluding (B) frames of  the 















AMK’s location over the course of the MD simulations are highly consistent with data 
from our previous 2D NMR titrations (Figure 4.9). Of the 8 residues that exhibited the largest 
AMK-mediated chemical shift perturbations in the N-terminal domain, residues F19 and 
particularly L4 were extremely close to AMK for large portions to the minimization simulation. 
Furthermore, Residues such as V55, A57 and E67, whose chemical shifts were greatly altered in 
NMR experiments, were proximal to AMK for almost the entirety of the production simulation. 
These findings strongly suggest that AMK interacts with the N-terminal domain through 
transient contacts within the N-terminal hydrophobic pocket in addition to locations towards the 







Figure 4.9 Heat map of AMK localization in the N-terminal domain over the course of 
minimization and production MD simulations. 
The location of AMK in the N-terminal domain over the course of the MD minimization and 
production simulations are shown in orange and red respectively. The darker the colouring, the 
longer AMK has spent in a given location. The sidechains of 8 residues that displayed the 
greatest chemical shift perturbation the 2D NMR titrations are shown. CaM and sidechains are 
depicted in beige, oxygen in red, nitrogen in blue and calcium ions in green. The structure was 
prepared using UCSF Chimera v. 1.13.1. 
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Models 5 and 9 were similarly analyzed using MD simulations as they were within the 
hydrophobic cavities of the N- and C-terminal domains respectively and agreed with 
experimentally determined NMR data. During simulations beginning with the model 5 pose, 
AMK migrates towards to outer edges of the hydrophobic cavity where it remains throughout the 
production run, remaining relatively close to the reference residue F19 (Figure 4.9A). The ligand 
alternates from being wedged between the first helical segment of EF hand 1 and either the 
second helical region of the same EF hand, or the helical region preceding the central linker 
region. Although AMK did not dissociate, the interaction was far more dynamic than its N-
terminal contemporary in model 1 and thus a static representation of binding is not feasible. 
Model 9-initiated simulations did not produce a stable binding mode. During equilibration, AMK 
exits the hydrophobic cavity and explores the protein surface. This is represented by the extreme 
fluctuations in O1 and N2 distances, with local maxima as high as 85 Å (Figure 4.9B). For C-
terminal poses, the a-carbons I100 and V136 were selected as reference points. No other pose 
selected for MD analysis produced a plausible binding mode, with AMK completely dissociating 
from CaM altogether. 
Regardless of the localization of the ligand during the simulations, no significant changes 
were seen in the overall architecture of CaM. N- and C-terminal domains maintain their 
orientational freedom, remaining completely separate throughout as seen in NMR structures of 














Figure 4.10 Model 5 and model 9 MD production trajectories. 
(A) The change in distance between Ca of I63 and O1 of AMK (black), Ca of F19 and O1 of 
AMK (red), Ca of F19 and N2 of AMK (green) and Ca of I63 and N2 of AMK (blue) during the 
model 5 production simulation. (B) The change in distance between Ca of V136 and O1 of AMK 
(black), Ca of I100 and O1 of AMK (red), Ca of I100 and N2 of AMK (green) and Ca of V136 






























Weak association is further substantiated by the limited number of stable or near-stable binding 
modes. Only sites inside or in the immediate vicinity of the N-terminal hydrophobic cavity 
remained relatively close to their starting positions. This is in agreement with 15N-HSQC titration 
data from the previous chapter which described a marginally higher affinity for the N-terminal 
domain, yet contrasts behaviour seen with antagonists such as TFP whose contacts with CaM are 
extensively biased towards the C-terminal domain.59 
 
4.3.2.2 Molecular Dynamics Simulations of AMK-nNOS Peptide Complexation 
 20 ns simulations involving AMK and nNOS peptide did not show the formation of a 
stable complex. The ligand appears to scavenge the surface of the peptide until approximately 
4.9 ns, at which point it no longer associates with nNOS and moves freely around the unit cell 









Figure 4.11 Visual CaM-nNOS MD trajectory. 
The production MD trajectory of AMK and nNOS from the highest affinity docking pose. The 
initial position is seen in panel one, dissociation occurring at 4.9 ns is seen in panel two and AMK 
returns in close proximity to the peptide from 10.6 ns onward as seen in panel three. The peptide is 
shown in beige and AMK in cyan. Oxygens are shown in red, hydrogens in white and nitrogens in 
blue. The structures were prepared using USCF Chimera v 1.13.1. 
0 ns 4.9 ns 10.6 ns 
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After 10.6 ns, AMK again moves along the surface of the peptide, forming fleeting contacts 
along the way. Little can be inferred in terms of biological relevance from these results.  
 
4.3.3.3 Molecular Dynamics Simulations of AMK-CaM-nNOS Peptide Complexation 
 
 MD simulations were carried out to approximate what allosteric binding of AMK to the 
CaM-nNOS peptide complex might look like. The model 1 (the most energetically favourable 
pose) docking pose was selected as the starting point for the simulation. The RMSD plot from 
the 10 ns minimization and equilibration showed a sufficiently minimized system for production 
simulations (Figure 4.12). Ove the course of the 10 ns, AMK migrated from between the ends to 
the N- and C-terminal domains towards the N-terminal. Here, it wedges itself between the first 




Figure 4.12 RMSD of AMK-CaM-nNOS minimization MD simulation. 
RMSD of a 10 ns minimization and equilibration with model 1 used to generate starting 






This position is not unlike that which AMK assumes during the model 1 CaM-AMK 
minimization simulation. The 20 ns production simulation saw little change in localization with 
respect to the final frame of the minimization run. The binding mode appears to be relatively 
stable, with AMK remaining firmly wedged between the N-terminal tail and the central linker 
region, near hydrophobic residues such as L4, F12, L4, L69 and M71 (Figure 4.14). In this 
position, the amine group near the phenyl moiety in AMK forms hydrogen bonds with 
backbones of nearby residues. Oxygen-containing segments of AMK also associate 
electrostatically with R74 in a highly transient manner. Many of these residues, particularly L4, 
L69 and R74, are the same residues that exhibited among the largest AMK-mediated chemical 
shift perturbations in our 2D NMR titrations.  
 
0 ns 10 ns 
Figure 4.13 Visual AMK-CaM-nNOS minimization MD trajectory. 
The minimization MD trajectory of AMK and the CaM-nNOS peptide complex from the highest 
affinity docking pose. CaM is shown in beige, the peptide is red and AMK in cyan. The structures 






The results of these MD studies add to the compiling evidence suggesting that AMK does 
not bind to CaM particularly strongly. The interaction appears to be weak and highly dynamic 
based on the extremely mobile nature of AMK throughout each simulation, even in its most 
stable binding modes. It is, therefore, not surprising that such a complex would not be amenable 
to more conventional NOE-based NMR structure determination methods. MD simulations are in 
agreement with our 2D NMR titration data; residues in CaM closest to AMK during the 
simulations closely mirror the residues that exhibited large, AMK-mediated changes in chemical 
shifts. AMK appears to situate itself within the hydrophobic cavity in a highly dynamic fashion. 
MD simulations also revealed a reasonable prediction of an AMK-CaM-nNOS complex in which 
AMK might exert allosteric effects. During these simulations, AMK primarily associates with 
Figure 4.14 Proximal residues to AMK during the production MD simulation. 
Residues in close proximity to, and interacting with CaM are shown. CaM and sidechains are 
shown in beige and AMK in cyan. Oxygen is depicted in red, nitrogen in blue, hydrogen in white 
and sulphur in yellow. The structures were prepared using USCF Chimera v 1.13.1. 
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the linker region and the N-terminal tail, which also exhibits a likely binding surface as per the 
2D NMR titrations. How such a complex might cause inhibition of nNOS in a more biologically 
relevant environment remains to be elucidated. 
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Chapter 5  
Summary and Future Work 
 
5.1 Summary 
 In Chapter 2, the strength of binding between CaM and prospective antagonists aMT and 
AMK was interrogated under saturated Ca2+ conditions using an array of biophysical techniques. 
Far-UV CD showed no saturable interaction involving AMK, and less so in the case of aMT. 
Furthermore, the large decreases in a-helical signal are likely the result of optical activity of the 
compounds, particularly aMT, as opposed to veritable alterations in secondary structure. Near-
UV CD showed no change in molar ellipticity induced by either compound. AMK and aMT were 
similarly ineffective in impacting the electrophoretic mobility of CaM in the presence and 
absence of stoichiometric amounts of nNOS peptide, even at significantly elevated 
concentrations. ITC experiments failed to produce a viable isotherm necessary to generate 
parameters to quantify CaM-AMK binding. Oxyhemoglobin capture assays with AMK showed 
no reduction in enzyme activity regardless of ligand concentration. There were, however, 
suggestions of isoform-dependent reduction in affinity between CaM and nNOS induced by 
AMK. SPR competition experiments revealed a notable reduction in Kd values for nNOS (albeit 
mainly at extremely high levels of ligand), but such an occurrence was not observed with eNOS. 
Furthermore, the change in molar ellipticity during far-UV CD titrations upon CaM 
complexation with the nNOS peptide was observably reduced when CaM was pre-incubated with 
AMK. The same was not seen with any other NOS isoform. CaM-nNOS and CaM-eNOS 
isotherms were also significantly modified by the presence of AMK during ITC competition 
assays. Two overarching conclusions can be drawn from these experiments; the association 
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between CaM and AMK is weak, and AMK may have a subtle capacity to selectively modulate 
CaM-nNOS peptide complex formation. 
 In Chapter 3, NMR spectroscopy was used to conduct a more refined structural detailing 
of AMK interactions with CaM. Solution structures of CaM when bound to AMK in Ca2+-
saturating conditions closely resembled unbound holo-CaM, with the N-and C-terminal globular 
domains retaining their orientational independence from one another. It appears that AMK is 
unable to cause the significant structural rearrangements seen when CaM binds to biological 
targets or antagonists such as TFP.58,59 Similar independence of globular domains was, however, 
seen in interactions with antagonists such as W-7 in previous studies.122 Furthermore, no 
intermolecular NOEs could be observed between CaM and AMK, consistent with a very low 
affinity system. Monitoring of chemical shift perturbations of isotopically labelled CaM induced 
by AMK were observed as a means to quantify association. Approximately one third of residues 
exhibited significant changes in chemical shifts, distributed equally across both domains. The 
largest of these changes occurred within the hydrophobic pockets that are exposed upon CaM 
binding to Ca2+. Independent fitting by non-linear regression yielded Kd values of approximately 
3 mM, with the N-terminal displaying a marginally higher affinity. The overall conformation of 
CaM when bound to AMK and the likely binding surfaces indicate that AMK may act as a much 
weaker analogue of compounds such as W-7. 
 In Chapter 4, computational methods were used to visualize the dynamic relationship 
between CaM and AMK. Molecular docking simulations identified six docking sites according 
to free energy scoring; four on the N-terminal domain and two on the C-terminal domain. 
Representative poses from the various docking sites were selected for MD simulations with the 
only stable binding modes localized to the N-terminal. These modes are situated in the 
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hydrophobic cavity and characterized by close proximity to hydrophobic methionine residues 
and polar contacts with negatively charged aspartate and glutamate residues in the globular 
domain and a positively charged lysine near the central linker. A similar protocol was followed 
to analyze interactions between the ligand and the nNOS peptide, but no stable binding was 
observed, with AMK completely dissociating as the simulations progressed. MD simulations 
were also employed to replicate a system involving AMK, CaM and the nNOS peptide. These 
simulations produced a relatively stable binding mode in which AMK occupied the site between 
the N-terminal tail of CaM and the central helical region. Such a complex is plausible given that 
many of the same residues proximal to the ligand also exhibited large chemical shift changes in 
our 2D NMR titrations involving CaM and AMK. How nNOS might be inhibited in such a 
complex in a physiological setting remains unknown.  
Collectively, our results are confirmation of a similar interaction between CaM and AMK 
as previously seen in the case of CaM and aMT. Both proceed with very low affinities and 
affecting similar regions of the protein. The nature of this interaction suggests that a potent 
competition for the hydrophobic binding sites in CaM (as exhibited by antagonists such as W-7) 
or limiting availability of binding regions through inducing major conformational changes (as 
seen with TFP) are not likely. Instead, inhibition is likely achieved through a gentle modulation 
of protein function via allosteric interaction with a CaM-nNOS complex. 
  
5.2 Recommendations for Future Work 
5.2.1 Binding Analysis under Physiological Ca2+ Concentrations. 
 Experimental work in the present study was conducted under saturating Ca2+ conditions. 
There is evidence to suggest that the antagonistic effects of AMK may be amplified under 
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physiological Ca2+ concentrations ranging from 100-225 nM, as CaM has been shown to 
associate more loosely with NOS when in a partially Ca2+-replete state. This may help bridge the 
gap between enzyme inhibition seen in vivo and the low affinities seen in our experiments.  
 
5.2.2 Recreation of Previously Conducted Biophysical Analyses 
 This analysis of AMK and its potential antagonism of CaM would be made stronger still 
if certain biophysical experiments could reproduce the results of previously conducted studies. 
Most importantly, replicating the inhibition of nNOS in vitro would greatly complement our 
structural data. It is possible that alteration of protocol or enzyme source may yield the desired 
effect. Further optimization of our gel mobility assays would also prove to be highly useful. It is 
especially strange that our assays did not show effects show in prior studies, given that 
experimental conditions were identical.  
 
5.2.3 Solution Structure of CaM-AMK in complex with nNOS. 
 Despite the absence of intermolecular NOEs between AMK and CaM, it may be 
worthwhile to obtain solution structures of CaM bound to the NOS peptides in the presence of 
AMK. Although the localization of the ligand itself may be hard to pinpoint, any influences upon 
the complexation between the protein and the peptide should be apparent when comparing 
resonance assignments to existing NMR datasets.  
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Appendix A 













Lysogeny Broth medium 
(per litre) 
10 g tryptone 
5 g yeast extract 
5 g NaCl 
100 μL 10 N NaOH 
15 g agar (for plates) 
M9 Medium (per litre) 
6 g Na2HPO4  7H2O 
3 g KH2PO4 
0.5 g NaCl 
1 mL 1000X micronutrients 
1 mL 2 M MgSO4 
100 μL 1 M CaCl2 
100 μL 10 mM FeSO4 
10 mL 1 M 13C6 D-glucose 
10 mL 2 M 15NH4Cl  
1000X micronutrient Stock 
(per 100 mL) 
30 μL 10 mM (NH4)6Mo7O24 
1 mL 40 mM H3BO3 
300 μL 10 mM CoCl2 
100 μL 10 mM CuSO4 
800 μL 10 mM MnCl2  7H2O 
100 μL 10 mM ZnCl2 
CaM Fractions CaM Fractions 
SDS PAGE Gel of Purified CaM Fractions 
CaM Standard 
Lane 1: CaM standard 
Lanes 2-6: Weak CaM fractions 
Lanes 7-11: Strong CaM fractions 
Lane 12: Rainbow protein standard 
Lanes 1-5: Strong CaM fractions 
Lanes 6-11: Cellular debris fractions 
Lane 12: Rainbow protein standard 
 96 
Appendix B 
 NMR Pulse Program Information
15N-HSQC:  




;2D H-1/X correlation via double inept transfer 
; using sensitivity improvement 
;phase sensitive using Echo/Antiecho-TPPI gradient selection  
;with decoupling during acquisition 
;using trim pulses in inept transfer 
;using f3 - channel 
;A.G. Palmer III, J. Cavanagh, P.E. Wright & M. Rance, J. Magn.  
; Reson. 93, 151-170 (1991) 
;L.E. Kay, P. Keifer & T. Saarinen, J. Am. Chem. Soc. 114, ; 
10663-5 (1992) 
;J. Schleucher, M. Schwendinger, M. Sattler, P. Schmidt, O. 
Schedletzky, 
; S.J. Glaser, O.W. Sorensen & C. Griesinger, J. Biomol. NMR 4, 
; 301-306 (1994)  
HNCA:  
# 1 "/opt/xwinnmr/exp/stan/nmr/lists/pp/hncagp3d" ;hncagp3d 
;avance-version (02/05/31) 
;HNCA  
;3D sequence with 
; inverse correlation for triple resonance using multiple 
; inept transfer steps 
; F1(H) -> F3(N) -> F2(Ca,t1) -> F3(N,t2) -> F1(H,t3) ;on/off 
resonance Ca and C=O pulses using shaped pulse ;phase sensitive 
(t1) 
;phase sensitive using Echo/Antiecho gradient selection (t2) ;using 
constant time in t2 
;(use parameterset HNCAGP3D) 
;S. Grzesiek & A. Bax, J. Magn. Reson. 96, 432 - 440 (1992) 
;(J. Schleucher, M. Sattler & C. Griesinger, Angew. Chem. Int. Ed. 
32, 
; 1489-1491 (1993)) 
;(L.E. Kay, G.Y. Xu & T. Yamazaki, J. Magn. Reson. A109, 129-
133 (1994)) 
prosol relations=<triple>  
HNcoCA:  
# 1 "/opt/xwinnmr/exp/stan/nmr/lists/pp/hncocagp3d" ;hncocagp3d 
;avance-version (03/08/05)  
;HN(CO)CA 
;3D sequence with 
; inverse correlation for triple resonance using multiple 
; inept transfer steps 
; F1(H) -> F3(N) -> F2(C=O) -> F2(Ca,t1) 
; -> F2(C=O) -> F3(N,t2) -> F1(H,t3) 
;on/off resonance Ca and C=O pulses using shaped pulse ;phase 
sensitive (t1) 
;phase sensitive using Echo/Antiecho gradient selection (t2) ;using 
constant time in t2 
;(use parameterset HNCOCAGP3D) 
;S. Grzesiek & A. Bax, J. Magn. Reson. 96, 432 - 440 (1992) 
;(L.E. Kay, G.Y. Xu & T. Yamazaki, J. Magn. Reson. A109, 129-
133 (1994)) 
prosol relations=<triple>  
CBCAcoNH:  




;3D sequence with 
; inverse correlation for triple resonance using inept transfer steps 
; F1(H) -> F2(Caliph.,t1 -> Ca) -> F2(C=O) -> F3(N,t2) -> 
F1(H,t3) 
;on/off resonance Ca and C=O pulses using shaped pulse ;phase 
sensitive (t1) 
;phase sensitive (t2) 
;using constant time in t1 
;using constant time in t2 
;water suppression using watergate sequence 
;(use parameterset CBCACONHGPWG3D) 
;S. Grzesiek & A. Bax, J. Biomol. NMR 3, 185-204 (1993) ;(D.R. 
Muhandiram & L.E. Kay, J. Magn. Reson. B 103, 203-216 (1994)) 
prosol relations=<triple>  





;3D sequence with 
; homonuclear correlation via dipolar coupling 
; dipolar coupling may be due to noe or chemical exchange. ; H-
1/X correlation via double inept transfer  
; using sensitivity improvement 
;phase sensitive (t1) 
;phase sensitive using Echo/Antiecho-TPPI gradient selection (t2) 
;using trim pulses in inept transfer 
;with decoupling during acquisition 
;using shaped pulses for inversion on f2 - channel 
;(use parameterset NOESYHSQCETGP3D) 
;A.L. Davis, J. Keeler, E.D. Laue & D. Moskau, J. Magn. Reson. 
98, 
; 207-216 (1992) 
;A.G. Palmer III, J. Cavanagh, P.E. Wright & M. Rance, J. Magn. 
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; Reson. 93, 151-170 (1991) 
;L.E. Kay, P. Keifer & T. Saarinen, J. Am. Chem. Soc. 114, ; 
10663-5 (1992) 
;J. Schleucher et al., Angew. Chem. 114(10), 1518 (1993)  
15N-NOESY HSQC:  





;3D sequence with 
; homonuclear correlation via dipolar coupling 
; dipolar coupling may be due to noe or chemical exchange ; H-1/X 
correlation via double inept transfer 
; using sensitivity improvement 
;phase sensitive (t1) 
;phase sensitive using Echo/Antiecho-TPPI gradient selection (t2) 
;with decoupling during acquisition 
;using flip-back pulse 
;using f3 - channel 
;(use parameterset NOESYHSQCFPF3GPSI3D) 
;O. Zhang, L.E. Kay, J.P. Olivier & J.D. Forman-Kay, 
; J. Biomol. NMR 4, 845 - 858 (1994) 
;A.G. Palmer III, J. Cavanagh, P.E. Wright & M. Rance, J. Magn. 
; Reson. 93, 151-170 (1991) 
;L.E. Kay, P. Keifer & T. Saarinen, J. Am. Chem. Soc. 114, ; 
10663-5 (1992) 
;J. Schleucher, M. Schwendinger, M. Sattler, P. Schmidt, O. 
Schedletzky, 
; S.J. Glaser, O.W. Sorensen & C. Griesinger, J. Biomol. NMR 4, 
; 301-306 (1994) 
prosol relations=<triple>  
15N-double-filtered NOESY:  
# 1 "C:/Bruker/XWIN- 
NMR/exp/stan/nmr/lists/pp/noesygpphwgxf" ;noesygpphwgxf 
;avance-version (02/02/07)  
;2D homonuclear correlation via dipolar coupling 
;dipolar coupling may be due to noe or chemical exchange ;phase 
sensitive 
;selecting C-12 or N-14 bound protons in F1 and F2 
;water suppression using watergate sequence 
; 
;M. Ikura & A. Bax, J. Am. Chem. Soc. 114, 2433-2440 (1992) 
;M. Piotto, V. Saudek & V. Sklenar, J. Biomol. NMR 2, 661 - 666 
(1992) 
;V. Sklenar, M. Piotto, R. Leppik $ V. Saudek, J. Magn. Reson., 
; Series A 102, 241 -245 (1993)  
HC(C)H-TOCSY:  




;3D sequence with 
; inverse correlation using multiple inept transfer and 
; C-C DIPSI3 spinlock 
; F1(H,t1) -> F2(C,t2) -> F2(C') -> F1(H',t3) 
;off resonance C=O pulse using shaped pulse 
;phase sensitive (t1) 
;phase sensitive (t2) 
;spinlock during z-filter 
;(use parameterset HCCHDIGP3D) 
;(L.E. Kay, G.Y. Xu, A.U. Singer, D.R. Muhandiram & J. D. 
Forman-Kay 
; J. Magn. Reson. B 101, 333 - 337 (1993)) 
prosol relations=<triple>  
(H)CCH-TOCSY:  
# 1 "C:/Bruker/XWIN- NMR/exp/stan/nmr/lists/pp/hcchdigp3d2" 
;hcchdigp3d2 
;avance-version (02/07/16) ;HCCH-TOCSY 




;off resonance C=O pulse using shaped pulse ;phase sensitive (t1)  
inverse correlation using multiple inept transfer and C-C DIPSI3 
spinlock 
F1(H) -> F2(C,t1) -> F2(C',t2) -> F1(H',t3)  
;phase sensitive (t2) 
;spinlock during z-filter 
;(use parameterset HCCHDIGP3D2) 
;(L.E. Kay, G.Y. Xu, A.U. Singer, D.R. Muhandiram & J. D. 
Forman-Kay 









CaM-AMK Assigned Chemical Shifts 
 
 
  1   ALA  CA    C  51.770 
  1   ALA  CB    C  15.092 
  1   ALA  H     H   8.316 
  1   ALA  HA    H   4.066 
  1   ALA  HB    H   1.343 
  1   ALA  N     N 123.948 
  3   GLN  CA    C  56.734 
  3   GLN  CB    C  25.300 
  3   GLN  CG    C  31.255 
  3   GLN  H     H   7.787 
  3   GLN  HA    H   3.833 
  3   GLN  HB2   H   2.092 
  3   GLN  HG2   H   2.363 
  3   GLN  N     N 118.748 
  4   LEU  CA    C  56.559 
  4   LEU  CB    C  39.755 
  4   LEU  CG    C  23.297 
  4   LEU  CD1   C  21.186 
  4   LEU  CD2   C  19.995 
  4   LEU  H     H   7.572 
  4   LEU  HA    H   3.993 
  4   LEU  HB2   H   1.839 
  4   LEU  HB3   H   1.753 
  4   LEU  HG    H   1.522 
  4   LEU  HD1   H   0.798 
  4   LEU  HD2   H   0.753 
  4   LEU  N     N 122.359 
  5   THR  CA    C  57.755 
  5   THR  CB    C  68.455 
  5   THR  CG2   C  19.013 
  5   THR  H     H   8.624 
  5   THR  HA    H   4.391 
  5   THR  HB    H   4.749 
  5   THR  HG2   H   1.286 
  5   THR  N     N 113.769 
  6   GLU  CA    C  57.291 
  6   GLU  CB    C  25.772 
  6   GLU  CG    C  33.545 
  6   GLU  H     H   8.894 
  6   GLU  HA    H   3.973 
  6   GLU  HB2   H   2.063 
  6   GLU  HB3   H   2.009 
  6   GLU  HG2   H   2.360 
  6   GLU  HG3   H   2.306 
  6   GLU  N     N 121.153 
  7   GLU  CA    C  55.760 
  7   GLU  CB    C  26.455 
  7   GLU  CG    C  33.296 
  7   GLU  H     H   8.600 
  7   GLU  HA    H   4.062 
  7   GLU  HB2   H   2.063 
  7   GLU  HB3   H   2.018 
  7   GLU  HG2   H   2.353 
  7   GLU  HG3   H   2.308 
  7   GLU  N     N 120.295 
  8   GLN  CA    C  56.502 
  8   GLN  CB    C  25.436 
  8   GLN  CG    C  31.228 
  8   GLN  H     H   7.621 
  8   GLN  HA    H   3.796 
  8   GLN  HB2   H   2.086 
  8   GLN  HB3   H   2.086 
  8   GLN  HG2   H   2.371 
  8   GLN  HG3   H   2.371 
  8   GLN  N     N 121.167 
  9   ILE  CA    C  63.522 
  9   ILE  CB    C  35.033 
  9   ILE  CG1   C  27.324 
  9   ILE  CG2   C  14.619 
  9   ILE  CD1   C  10.275 
  9   ILE  H     H   8.248 
  9   ILE  HA    H   3.656 
  9   ILE  HB    H   1.903 
  9   ILE  HG12  H   1.066 
  9   ILE  HG2   H   1.018 
  9   ILE  HD1   H   0.819 
  9   ILE  N     N 120.276 
 10   ALA  CA    C  52.705 
 10   ALA  CB    C  15.276 
 10   ALA  H     H   7.864 
 10   ALA  HA    H   4.038 
 10   ALA  HB    H   1.486 
 10   ALA  N     N 121.903 
 11   GLU  CA    C  56.688 
 11   GLU  CB    C  25.733 
 11   GLU  CG    C  33.312 
 11   GLU  H     H   7.648 
 11   GLU  HA    H   3.983 
 11   GLU  HB2   H   2.069 
 11   GLU  HB3   H   2.009 
 11   GLU  HG2   H   2.362 
 11   GLU  HG3   H   2.310 
 11   GLU  N     N 120.402 
 12   PHE  CA    C  56.502 
 12   PHE  CB    C  34.985 
 12   PHE  H     H   8.448 
 12   PHE  HA    H   4.997 
 12   PHE  HB2   H   3.480 
 12   PHE  HB3   H   3.398 
 12   PHE  N     N 120.961 
 13   LYS  CA    C  57.430 
 13   LYS  CB    C  29.496 
 13   LYS  CG    C  21.808 
 13   LYS  CD    C  25.923 
 13   LYS  CE    C  39.240 
 13   LYS  H     H   9.079 
 13   LYS  HA    H   3.956 
 13   LYS  HB2   H   1.824 
 13   LYS  HB3   H   1.824 
 13   LYS  HG2   H   1.349 
 13   LYS  HG3   H   1.349 
 13   LYS  HD2   H   1.615 
 13   LYS  HD3   H   1.615 
 13   LYS  HE2   H   2.941 
 13   LYS  HE3   H   2.941 
 13   LYS  N     N 124.361 
 14   GLU  CA    C  56.471 
 14   GLU  CB    C  26.166 
 14   GLU  CG    C  33.204 
 14   GLU  H     H   7.649 
 14   GLU  HA    H   3.994 
 14   GLU  HB2   H   2.060 
 14   GLU  HB3   H   2.010 
 14   GLU  HG2   H   2.372 
 14   GLU  HG3   H   2.309 
 14   GLU  N     N 121.109 
 15   ALA  CA    C  52.574 
 15   ALA  CB    C  15.508 
 15   ALA  H     H   7.857 
 15   ALA  HA    H   4.236 
 15   ALA  HB    H   1.917 
 15   ALA  N     N 123.422 
 16   PHE  CA    C  59.286 
 16   PHE  CB    C  37.045 
 16   PHE  H     H   8.686 
 16   PHE  HA    H   3.196 
 16   PHE  HB2   H   3.133 
 16   PHE  HB3   H   3.133 
 16   PHE  N     N 120.047 
 17   SER  CA    C  58.822 
 17   SER  CB    C  60.552 
 17   SER  H     H   7.830 
 17   SER  HA    H   4.087 
 17   SER  HB2   H   3.996 
 17   SER  N     N 113.565 
 18   LEU  CA    C  54.437 
 18   LEU  CB    C  39.430 
 18   LEU  CG    C  23.405 
 18   LEU  CD1   C  21.348 
 18   LEU  CD2   C  19.941 
 18   LEU  H     H   7.261 
 18   LEU  HA    H   4.079 
 18   LEU  HB2   H   1.837 
 18   LEU  HB3   H   1.769 
 18   LEU  HG    H   1.524 
 18   LEU  HD1   H   0.794 
 18   LEU  HD2   H   0.759 
 18   LEU  N     N 121.520 
 19   PHE  CA    C  56.595 
 19   PHE  CB    C  38.157 
 19   PHE  H     H   7.123 
 19   PHE  HA    H   4.229 
 19   PHE  HB2   H   2.632 
 19   PHE  HB3   H   2.632 
 19   PHE  N     N 115.449 
 20   ASP  CA    C  49.497 
 20   ASP  CB    C  35.744 
 20   ASP  H     H   7.692 
 20   ASP  HA    H   4.511 
 20   ASP  HB2   H   1.479 
 20   ASP  HB3   H   1.458 
 20   ASP  N     N 118.306 
 21   LYS  CA    C  55.760 
 21   LYS  CB    C  29.929 
 21   LYS  CG    C  21.808 
 21   LYS  CD    C  26.031 
 21   LYS  CE    C  39.349 
 21   LYS  H     H   7.545 
 21   LYS  HA    H   3.971 
 21   LYS  HB2   H   1.824 
 21   LYS  HB3   H   1.824 
 21   LYS  HG2   H   1.348 
 21   LYS  HG3   H   1.348 
 21   LYS  HD2   H   1.634 
 21   LYS  HD3   H   1.634 
 21   LYS  HE2   H   2.941 
 21   LYS  HE3   H   2.941 
 21   LYS  N     N 125.092 
 22   ASP  CA    C  50.100 
 22   ASP  CB    C  37.452 
 22   ASP  H     H   7.902 
 22   ASP  HA    H   4.557 
 22   ASP  HB2   H   3.018 
 22   ASP  HB3   H   3.018 
 22   ASP  N     N 114.556 
 23   GLY  CA    C  44.486 
 23   GLY  H     H   7.546 
 23   GLY  HA2   H   3.818 
 23   GLY  HA3   H   3.818 
 23   GLY  N     N 109.956 
 24   ASP  CA    C  51.121 
 24   ASP  CB    C  38.387 
 24   ASP  H     H   8.249 
 24   ASP  HA    H   4.446 
 24   ASP  HB2   H   2.911 
 24   ASP  HB3   H   2.911 
 24   ASP  N     N 121.400 
 25   GLY  CA    C  42.909 
 25   GLY  H     H  10.500 
 25   GLY  HA2   H   4.328 
 25   GLY  HA3   H   4.326 
 25   GLY  N     N 113.852 
 26   THR  CA    C  57.059 
 26   THR  CB    C  69.832 
 26   THR  CG2   C  18.870 
 26   THR  H     H   8.002 
 26   THR  HA    H   5.278 
 26   THR  HB    H   3.810 
 26   THR  HG2   H   0.983 
 26   THR  N     N 113.489 
 27   ILE  CA    C  57.709 
 27   ILE  CB    C  36.982 
 27   ILE  CG1   C  24.349 
 27   ILE  CG2   C  14.817 
 27   ILE  CD1   C  12.648 
 27   ILE  H     H   9.691 
 27   ILE  HA    H   4.928 
 27   ILE  HB    H   1.742 
 27   ILE  HG12  H   0.265 
 27   ILE  HG2   H   0.837 
 27   ILE  HD1   H   0.216 
 27   ILE  N     N 127.639 
 28   THR  CA    C  56.690 
 28   THR  CB    C  69.890 
 28   THR  CG2   C  18.637 
 28   THR  H     H   8.287 
 28   THR  HA    H   4.776 
 28   THR  HB    H   4.786 
 28   THR  HG2   H   1.286 
 28   THR  N     N 117.149 
 29   THR  CA    C  63.701 
 29   THR  CB    C  65.547 
 29   THR  CG2   C  19.397 
 29   THR  H     H   8.988 
 29   THR  HA    H   3.697 
 29   THR  HB    H   4.245 
 29   THR  HG2   H   1.218 
 29   THR  N     N 113.487 
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 30   LYS  H     H   7.400 
 30   LYS  N     N 120.979 
 31   GLU  CA    C  56.456 
 31   GLU  CB    C  26.600 
 31   GLU  CG    C  33.421 
 31   GLU  H     H   7.532 
 31   GLU  HA    H   4.062 
 31   GLU  HB2   H   2.072 
 31   GLU  HB3   H   2.013 
 31   GLU  HG2   H   2.356 
 31   GLU  HG3   H   2.302 
 31   GLU  N     N 121.579 
 32   LEU  CA    C  55.308 
 32   LEU  CB    C  39.705 
 32   LEU  CG    C  23.351 
 32   LEU  CD1   C  21.186 
 32   LEU  CD2   C  19.887 
 32   LEU  H     H   8.582 
 32   LEU  HA    H   4.083 
 32   LEU  HB2   H   1.841 
 32   LEU  HB3   H   1.752 
 32   LEU  HG    H   1.522 
 32   LEU  HD1   H   0.802 
 32   LEU  HD2   H   0.757 
 32   LEU  N     N 121.387 
 33   GLY  CA    C  45.646 
 33   GLY  H     H   8.527 
 33   GLY  HA2   H   3.942 
 33   GLY  HA3   H   3.942 
 33   GLY  N     N 106.367 
 34   THR  CA    C  64.247 
 34   THR  CB    C  66.035 
 34   THR  CG2   C  18.854 
 34   THR  H     H   7.757 
 34   THR  HA    H   3.878 
 34   THR  HB    H   4.285 
 34   THR  HG2   H   1.228 
 34   THR  N     N 118.306 
 35   VAL  CA    C  63.601 
 35   VAL  CB    C  28.724 
 35   VAL  CG1   C  20.766 
 35   VAL  CG2   C  20.766 
 35   VAL  H     H   7.487 
 35   VAL  HA    H   3.489 
 35   VAL  HB    H   1.942 
 35   VAL  HG1   H   0.645 
 35   VAL  HG2   H   0.645 
 35   VAL  N     N 122.742 
 36   MET  CA    C  56.377 
 36   MET  CB    C  28.488 
 36   MET  CG    C  29.929 
 36   MET  CE    C  18.939 
 36   MET  H     H   8.359 
 36   MET  HA    H   4.092 
 36   MET  HB2   H   1.940 
 36   MET  HB3   H   1.940 
 36   MET  HG2   H   2.553 
 36   MET  HG3   H   2.553 
 36   MET  N     N 119.266 
 37   ARG  CA    C  57.180 
 37   ARG  CB    C  29.794 
 37   ARG  CG    C  25.950 
 37   ARG  CD    C  39.269 
 37   ARG  H     H   8.400 
 37   ARG  HA    H   4.786 
 37   ARG  HB2   H   1.830 
 37   ARG  HB3   H   1.830 
 37   ARG  HG2   H   1.614 
 37   ARG  HG3   H   1.614 
 37   ARG  HD2   H   2.941 
 37   ARG  HD3   H   2.941 
 37   ARG  N     N 119.685 
 38   SER  CA    C  56.290 
 38   SER  CB    C  61.040 
 38   SER  H     H   7.826 
 38   SER  HA    H   4.408 
 38   SER  HB2   H   3.917 
 38   SER  HB3   H   4.016 
 38   SER  N     N 119.447 
 39   LEU  CA    C  54.418 
 39   LEU  CB    C  39.542 
 39   LEU  CG    C  23.401 
 39   LEU  CD1   C  21.220 
 39   LEU  CD2   C  19.911 
 39   LEU  H     H   7.246 
 39   LEU  HA    H   4.074 
 39   LEU  HB2   H   1.754 
 39   LEU  HB3   H   1.754 
 39   LEU  HG    H   1.601 
 39   LEU  HD1   H   0.792 
 39   LEU  HD2   H   0.792 
 39   LEU  N     N 121.490 
 40   GLY  CA    C  42.816 
 40   GLY  H     H   7.721 
 40   GLY  HA2   H   4.205 
 40   GLY  HA3   H   4.205 
 40   GLY  N     N 107.609 
 41   GLN  CA    C  51.724 
 41   GLN  CB    C  27.687 
 41   GLN  CG    C  31.093 
 41   GLN  H     H   7.651 
 41   GLN  HA    H   4.453 
 41   GLN  HB2   H   1.595 
 41   GLN  HB3   H   1.595 
 41   GLN  HG2   H   2.200 
 41   GLN  HG3   H   2.200 
 41   GLN  N     N 119.165 
 42   ASN  CA    C  48.476 
 42   ASN  CB    C  35.994 
 42   ASN  H     H   8.587 
 42   ASN  HA    H   5.250 
 42   ASN  HB2   H   2.316 
 42   ASN  HB3   H   2.235 
 42   ASN  N     N 116.919 
 44   THR  CA    C  57.755 
 44   THR  CB    C  68.382 
 44   THR  CG2   C  19.046 
 44   THR  H     H   8.615 
 44   THR  HA    H   4.404 
 44   THR  HB    H   4.753 
 44   THR  HG2   H   1.286 
 44   THR  N     N 113.744 
 45   GLU  CA    C  57.198 
 45   GLU  CB    C  25.660 
 45   GLU  CG    C  33.467 
 45   GLU  H     H   8.674 
 45   GLU  HA    H   4.046 
 45   GLU  HB2   H   2.063 
 45   GLU  HB3   H   2.011 
 45   GLU  HG2   H   2.354 
 45   GLU  HG3   H   2.300 
 45   GLU  N     N 121.336 
 46   ALA  CA    C  52.280 
 46   ALA  H     H   8.135 
 46   ALA  HA    H   4.071 
 46   ALA  HB    H   1.338 
 46   ALA  N     N 121.491 
 47   GLU  CA    C  56.224 
 47   GLU  CB    C  26.563 
 47   GLU  CG    C  33.079 
 47   GLU  H     H   7.561 
 47   GLU  HA    H   3.989 
 47   GLU  HB2   H   2.073 
 47   GLU  HB3   H   2.011 
 47   GLU  HG2   H   2.354 
 47   GLU  HG3   H   2.306 
 47   GLU  N     N 119.459 
 48   LEU  CA    C  55.203 
 48   LEU  CB    C  39.646 
 48   LEU  CG    C  23.297 
 48   LEU  CD1   C  21.051 
 48   LEU  CD2   C  19.697 
 48   LEU  H     H   8.050 
 48   LEU  HA    H   4.084 
 48   LEU  HB2   H   1.839 
 48   LEU  HB3   H   1.769 
 48   LEU  HG    H   1.518 
 48   LEU  HD1   H   0.803 
 48   LEU  HD2   H   0.751 
 48   LEU  N     N 121.129 
 49   GLN  CA    C  55.806 
 49   GLN  CG    C  31.580 
 49   GLN  H     H   8.051 
 49   GLN  HA    H   3.789 
 49   GLN  HB2   H   2.087 
 49   GLN  HB3   H   2.087 
 49   GLN  HG2   H   2.372 
 49   GLN  HG3   H   2.372 
 49   GLN  N     N 118.961 
 50   ASP  CA    C  54.879 
 50   ASP  CB    C  37.640 
 50   ASP  H     H   7.951 
 50   ASP  HA    H   4.284 
 50   ASP  HB2   H   2.739 
 50   ASP  HB3   H   2.739 
 50   ASP  N     N 120.696 
 51   MET  CA    C  56.424 
 51   MET  CB    C  29.781 
 51   MET  CG    C  29.781 
 51   MET  CE    C  15.556 
 51   MET  H     H   7.766 
 51   MET  HA    H   4.008 
 51   MET  HB2   H   2.200 
 51   MET  HB3   H   2.200 
 51   MET  HG2   H   2.480 
 51   MET  HG3   H   2.480 
 51   MET  HE    H   1.925 
 51   MET  N     N 119.636 
 52   ILE  CA    C  61.977 
 52   ILE  CB    C  34.273 
 52   ILE  CG1   C  26.129 
 52   ILE  CG2   C  13.207 
 52   ILE  CD1   C   9.950 
 52   ILE  H     H   7.580 
 52   ILE  HA    H   3.474 
 52   ILE  HB    H   1.911 
 52   ILE  HG12  H   1.027 
 52   ILE  HG13  H   0.954 
 52   ILE  HD1   H   0.656 
 52   ILE  N     N 118.883 
 53   ASN  CA    C  53.162 
 53   ASN  CB    C  35.129 
 53   ASN  H     H   8.465 
 53   ASN  HA    H   4.351 
 53   ASN  HB2   H   2.950 
 53   ASN  HB3   H   2.950 
 53   ASN  N     N 118.347 
 54   GLU  CA    C  56.131 
 54   GLU  CB    C  26.491 
 54   GLU  CG    C  33.451 
 54   GLU  H     H   7.436 
 54   GLU  HA    H   3.984 
 54   GLU  HB2   H   2.065 
 54   GLU  HB3   H   2.008 
 54   GLU  HG2   H   2.351 
 54   GLU  HG3   H   2.310 
 54   GLU  N     N 117.149 
 55   VAL  CA    C  58.080 
 55   VAL  CB    C  30.091 
 55   VAL  CG1   C  18.939 
 55   VAL  CG2   C  18.939 
 55   VAL  H     H   7.059 
 55   VAL  HA    H   4.404 
 55   VAL  HB    H   2.304 
 55   VAL  HG1   H   0.779 
 55   VAL  HG2   H   0.779 
 55   VAL  N     N 109.605 
 56   ASP  CA    C  50.955 
 56   ASP  H     H   7.541 
 56   ASP  N     N 122.277 
 57   ALA  CA    C  51.584 
 57   ALA  CB    C  15.231 
 57   ALA  H     H   8.255 
 57   ALA  HA    H   4.061 
 57   ALA  HB    H   1.343 
 57   ALA  N     N 132.403 
 58   ASP  CA    C  50.146 
 58   ASP  CB    C  36.713 
 58   ASP  H     H   8.016 
 58   ASP  HA    H   4.537 
 58   ASP  HB2   H   3.027 
 58   ASP  HB3   H   3.027 
 58   ASP  N     N 114.404 
 59   GLY  CA    C  44.718 
 59   GLY  H     H   7.444 
 59   GLY  HA2   H   3.814 
 59   GLY  HA3   H   3.814 
 59   GLY  N     N 109.187 
 60   ASN  CA    C  56.468 
 60   ASN  CB    C  35.082 
 60   ASN  H     H   7.987 
 60   ASN  HA    H   5.003 
 60   ASN  HB2   H   3.483 
 60   ASN  HB3   H   3.483 
 60   ASN  N     N 119.224 
 61   GLY  CA    C  42.723 
 61   GLY  H     H  10.468 
 61   GLY  HA2   H   4.198 
 61   GLY  HA3   H   4.198 
 61   GLY  N     N 114.117 
 62   THR  CA    C  56.734 
 62   THR  CB    C  69.832 
 62   THR  CG2   C  18.870 
 62   THR  H     H   7.529 
 62   THR  HA    H   4.789 
 62   THR  HB    H   3.983 
 62   THR  HG2   H   1.255 
 62   THR  N     N 109.565 
 63   ILE  CA    C  57.013 
 63   ILE  CB    C  36.822 
 63   ILE  CG1   C  24.642 
 63   ILE  CG2   C  15.290 
 63   ILE  CD1   C  10.614 
 63   ILE  H     H   8.742 
 63   ILE  HA    H   5.148 
 63   ILE  HB    H   2.037 
 63   ILE  HG2   H   1.183 
 63   ILE  HD1   H   0.789 
 63   ILE  N     N 124.376 
 64   ASP  CA    C  49.311 
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 64   ASP  CB    C  36.375 
 64   ASP  H     H   8.679 
 64   ASP  HA    H   5.160 
 64   ASP  HB2   H   2.739 
 64   ASP  HB3   H   2.476 
 64   ASP  N     N 128.861 
 65   PHE  CA    C  60.724 
 65   PHE  CB    C  33.250 
 65   PHE  H     H   8.807 
 65   PHE  HA    H   3.951 
 65   PHE  HB2   H   2.774 
 65   PHE  HB3   H   2.774 
 65   PHE  N     N 119.342 
 67   GLU  CA    C  56.131 
 67   GLU  CB    C  26.564 
 67   GLU  CG    C  33.079 
 67   GLU  H     H   7.888 
 67   GLU  HA    H   4.110 
 67   GLU  HB2   H   2.070 
 67   GLU  HB3   H   2.014 
 67   GLU  HG2   H   2.353 
 67   GLU  HG3   H   2.306 
 67   GLU  N     N 118.370 
 68   PHE  CA    C  58.590 
 68   PHE  CB    C  36.747 
 68   PHE  H     H   8.685 
 68   PHE  HA    H   3.929 
 68   PHE  HB2   H   3.197 
 68   PHE  HB3   H   3.112 
 68   PHE  N     N 124.361 
 69   LEU  CA    C  55.210 
 69   LEU  CB    C  38.212 
 69   LEU  CG    C  22.891 
 69   LEU  CD2   C  21.159 
 69   LEU  H     H   8.336 
 69   LEU  HA    H   3.291 
 69   LEU  HB2   H   1.112 
 69   LEU  HB3   H   1.112 
 69   LEU  HG    H   0.958 
 69   LEU  HD2   H   0.569 
 69   LEU  N     N 119.876 
 70   THR  CA    C  63.694 
 70   THR  CB    C  65.313 
 70   THR  CG2   C  20.401 
 70   THR  H     H   7.422 
 70   THR  HA    H   3.757 
 70   THR  HB    H   4.248 
 70   THR  HG2   H   1.216 
 70   THR  N     N 116.349 
 71   MET  CA    C  56.595 
 71   MET  CB    C  29.942 
 71   MET  CG    C  29.563 
 71   MET  CE    C  15.907 
 71   MET  H     H   7.536 
 71   MET  HA    H   4.013 
 71   MET  HB2   H   2.006 
 71   MET  HB3   H   2.006 
 71   MET  HG2   H   2.311 
 71   MET  HG3   H   2.311 
 71   MET  HE    H   1.523 
 71   MET  N     N 122.388 
 72   MET  CA    C  53.023 
 72   MET  CB    C  29.278 
 72   MET  CG    C  29.448 
 72   MET  CE    C  15.053 
 72   MET  H     H   7.935 
 72   MET  HA    H   3.947 
 72   MET  HB2   H   1.065 
 72   MET  HB3   H   1.065 
 72   MET  HG2   H   1.252 
 72   MET  HG3   H   1.252 
 72   MET  HE    H   1.922 
 72   MET  N     N 117.760 
 73   ALA  CA    C  51.850 
 73   ALA  CB    C  15.556 
 73   ALA  H     H   8.083 
 73   ALA  HA    H   4.004 
 73   ALA  HB    H   1.352 
 73   ALA  N     N 122.962 
 74   ARG  H     H   7.314 
 74   ARG  N     N 116.847 
 75   LYS  CA    C  56.317 
 75   LYS  CB    C  29.604 
 75   LYS  CG    C  21.917 
 75   LYS  CD    C  25.815 
 75   LYS  CE    C  39.240 
 75   LYS  H     H   7.527 
 75   LYS  HA    H   3.985 
 75   LYS  HB2   H   1.828 
 75   LYS  HB3   H   1.828 
 75   LYS  HG2   H   1.430 
 75   LYS  HG3   H   1.430 
 75   LYS  HD2   H   1.629 
 75   LYS  HD3   H   1.629 
 75   LYS  HE2   H   2.946 
 75   LYS  HE3   H   2.946 
 75   LYS  N     N 119.423 
 76   MET  CA    C  53.950 
 76   MET  CB    C  29.577 
 76   MET  CG    C  29.577 
 76   MET  H     H   7.704 
 76   MET  HA    H   4.313 
 76   MET  HB2   H   2.132 
 76   MET  HB3   H   2.132 
 76   MET  HG2   H   2.614 
 76   MET  HG3   H   2.614 
 76   MET  N     N 119.163 
 77   LYS  CA    C  52.559 
 77   LYS  CB    C  29.279 
 77   LYS  CG    C  21.808 
 77   LYS  CD    C  26.248 
 77   LYS  CE    C  39.240 
 77   LYS  H     H   7.779 
 77   LYS  HA    H   4.326 
 77   LYS  HB2   H   1.748 
 77   LYS  HB3   H   1.748 
 77   LYS  HG2   H   1.355 
 77   LYS  HG3   H   1.355 
 77   LYS  HD2   H   1.623 
 77   LYS  HD3   H   1.623 
 77   LYS  HE2   H   2.939 
 77   LYS  HE3   H   2.939 
 77   LYS  N     N 121.137 
 78   ASP  CA    C  51.944 
 78   ASP  CB    C  38.563 
 78   ASP  H     H   8.129 
 78   ASP  HA    H   4.589 
 78   ASP  HB2   H   2.637 
 78   ASP  HB3   H   2.637 
 78   ASP  N     N 122.316 
 79   THR  CA    C  59.657 
 79   THR  CB    C  67.284 
 79   THR  CG2   C  18.637 
 79   THR  H     H   7.965 
 79   THR  HA    H   4.252 
 79   THR  HB    H   4.189 
 79   THR  HG2   H   1.130 
 79   THR  N     N 115.433 
 80   ASP  CA    C  51.677 
 80   ASP  CB    C  38.507 
 80   ASP  H     H   8.157 
 80   ASP  HA    H   4.583 
 80   ASP  HB2   H   2.523 
 80   ASP  HB3   H   2.523 
 80   ASP  N     N 123.859 
 81   SER  CA    C  56.595 
 81   SER  CB    C  60.922 
 81   SER  H     H   8.304 
 81   SER  HA    H   4.409 
 81   SER  HB2   H   3.918 
 81   SER  HB3   H   3.918 
 81   SER  N     N 117.940 
 82   GLU  CA    C  55.992 
 82   GLU  CB    C  26.418 
 82   GLU  CG    C  33.497 
 82   GLU  H     H   8.365 
 82   GLU  HA    H   4.072 
 82   GLU  HB2   H   2.062 
 82   GLU  HB3   H   2.007 
 82   GLU  HG2   H   2.358 
 82   GLU  HG3   H   2.307 
 82   GLU  N     N 123.180 
 83   GLU  CA    C  55.902 
 83   GLU  CB    C  26.127 
 83   GLU  CG    C  33.326 
 83   GLU  H     H   8.214 
 83   GLU  HA    H   4.094 
 83   GLU  HB2   H   2.069 
 83   GLU  HB3   H   2.001 
 83   GLU  HG2   H   2.297 
 83   GLU  HG3   H   2.356 
 83   GLU  N     N 120.409 
 84   GLU  CA    C  56.661 
 84   GLU  CB    C  26.419 
 84   GLU  CG    C  33.329 
 84   GLU  H     H   8.009 
 84   GLU  HA    H   4.074 
 84   GLU  HB2   H   2.062 
 84   GLU  HB3   H   2.008 
 84   GLU  HG2   H   2.374 
 84   GLU  HG3   H   2.315 
 84   GLU  N     N 119.430 
 85   ILE  CA    C  62.047 
 85   ILE  CB    C  34.695 
 85   ILE  CG1   C  26.092 
 85   ILE  CG2   C  16.073 
 85   ILE  CD1   C  10.301 
 85   ILE  H     H   7.892 
 85   ILE  HA    H   3.965 
 85   ILE  HB    H   2.117 
 85   ILE  HG12  H   1.043 
 85   ILE  HG13  H   1.043 
 85   ILE  HG2   H   1.043 
 85   ILE  HD1   H   0.743 
 85   ILE  N     N 122.881 
 86   ARG  CA    C  57.430 
 86   ARG  CB    C  29.631 
 86   ARG  CD    C  39.376 
 86   ARG  H     H   8.285 
 86   ARG  HA    H   3.963 
 86   ARG  HB2   H   1.821 
 86   ARG  HB3   H   1.771 
 86   ARG  HG2   H   1.647 
 86   ARG  HG3   H   1.624 
 86   ARG  HD2   H   2.946 
 86   ARG  HD3   H   2.935 
 86   ARG  N     N 122.450 
 87   GLU  CA    C  57.616 
 87   GLU  CB    C  25.556 
 87   GLU  CG    C  33.545 
 87   GLU  H     H   7.949 
 87   GLU  HA    H   3.978 
 87   GLU  HB2   H   2.072 
 87   GLU  HB3   H   2.012 
 87   GLU  HG2   H   2.359 
 87   GLU  HG3   H   2.303 
 87   GLU  N     N 119.254 
 88   ALA  CA    C  52.605 
 88   ALA  CB    C  15.122 
 88   ALA  H     H   7.769 
 88   ALA  HA    H   4.172 
 88   ALA  HB    H   1.736 
 88   ALA  N     N 122.950 
 89   PHE  CA    C  59.364 
 89   PHE  CB    C  36.662 
 89   PHE  H     H   8.406 
 89   PHE  HA    H   3.189 
 89   PHE  HB2   H   3.113 
 89   PHE  HB3   H   3.113 
 89   PHE  N     N 119.609 
 90   ARG  CA    C  56.131 
 90   ARG  CB    C  27.503 
 90   ARG  CG    C  24.792 
 90   ARG  CD    C  40.732 
 90   ARG  H     H   7.570 
 90   ARG  HA    H   3.839 
 90   ARG  HB2   H   1.923 
 90   ARG  HB3   H   1.923 
 90   ARG  HG3   H   1.841 
 90   ARG  HD2   H   3.165 
 90   ARG  HD3   H   3.165 
 90   ARG  N     N 116.501 
 91   VAL  CA    C  63.044 
 91   VAL  CB    C  28.883 
 91   VAL  CG1   C  19.966 
 91   VAL  CG2   C  19.966 
 91   VAL  H     H   7.382 
 91   VAL  HA    H   3.470 
 91   VAL  HB    H   2.108 
 91   VAL  HG1   H   0.970 
 91   VAL  HG2   H   0.970 
 91   VAL  N     N 119.033 
 92   PHE  CA    C  55.490 
 92   PHE  CB    C  37.479 
 92   PHE  H     H   7.401 
 92   PHE  HA    H   4.320 
 92   PHE  HB2   H   2.718 
 92   PHE  HB3   H   2.600 
 92   PHE  N     N 117.569 
 93   ASP  CA    C  49.497 
 93   ASP  CB    C  35.843 
 93   ASP  H     H   7.704 
 93   ASP  HA    H   4.509 
 93   ASP  HB2   H   1.315 
 93   ASP  HB3   H   1.315 
 93   ASP  N     N 117.577 
 94   LYS  CA    C  54.786 
 94   LYS  CB    C  30.579 
 94   LYS  CG    C  21.808 
 94   LYS  CD    C  26.031 
 94   LYS  CE    C  39.349 
 94   LYS  H     H   7.606 
 94   LYS  HA    H   4.082 
 94   LYS  HB2   H   1.765 
 94   LYS  HB3   H   1.765 
 94   LYS  HG2   H   1.348 
 94   LYS  HG3   H   1.348 
 94   LYS  HD2   H   1.625 
 94   LYS  HD3   H   1.625 
 94   LYS  HE2   H   2.941 
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 94   LYS  HE3   H   2.941 
 94   LYS  N     N 126.417 
 95   ASP  CA    C  50.217 
 95   ASP  CB    C  36.713 
 95   ASP  H     H   8.046 
 95   ASP  HA    H   4.496 
 95   ASP  HB2   H   3.025 
 95   ASP  HB3   H   3.025 
 95   ASP  N     N 114.652 
 96   GLY  CA    C  44.486 
 96   GLY  H     H   7.646 
 96   GLY  HA2   H   3.827 
 96   GLY  HA3   H   3.827 
 96   GLY  N     N 110.010 
 97   ASN  CA    C  49.914 
 97   ASN  CB    C  36.662 
 97   ASN  H     H   8.178 
 97   ASN  HA    H   4.528 
 97   ASN  HB2   H   2.608 
 97   ASN  HB3   H   2.608 
 97   ASN  N     N 120.276 
 98   GLY  CA    C  42.611 
 98   GLY  H     H  10.514 
 98   GLY  HA2   H   4.010 
 98   GLY  HA3   H   4.010 
 98   GLY  N     N 113.700 
 99   TYR  CA    C  53.348 
 99   TYR  CB    C  40.340 
 99   TYR  H     H   7.480 
 99   TYR  HA    H   5.019 
 99   TYR  HB2   H   2.509 
 99   TYR  HB3   H   2.461 
 99   TYR  N     N 116.539 
100   ILE  CA    C  57.755 
100   ILE  CG1   C  24.142 
100   ILE  CG2   C  14.817 
100   ILE  CD1   C  12.648 
100   ILE  H     H   9.994 
100   ILE  HA    H   4.923 
100   ILE  HB    H   1.752 
100   ILE  HG12  H   0.262 
100   ILE  HG2   H   0.841 
100   ILE  HD1   H   0.212 
100   ILE  N     N 127.958 
101   SER  CA    C  53.116 
101   SER  CB    C  63.664 
101   SER  H     H   8.804 
101   SER  HA    H   4.815 
101   SER  HB2   H   3.950 
101   SER  HB3   H   3.950 
101   SER  N     N 124.494 
102   ALA  CA    C  53.116 
102   ALA  CB    C  15.201 
102   ALA  H     H   9.079 
102   ALA  HA    H   3.899 
102   ALA  HB    H   1.419 
102   ALA  N     N 123.653 
103   ALA  CA    C  52.466 
103   ALA  CB    C  15.596 
103   ALA  H     H   8.111 
103   ALA  HA    H   3.984 
103   ALA  HB    H   1.352 
103   ALA  N     N 119.056 
104   GLU  CA    C  56.688 
104   GLU  CB    C  25.551 
104   GLU  CG    C  33.358 
104   GLU  H     H   7.737 
104   GLU  HA    H   4.001 
104   GLU  HB2   H   2.066 
104   GLU  HB3   H   2.009 
104   GLU  HG2   H   2.362 
104   GLU  HG3   H   2.315 
104   GLU  N     N 120.549 
105   LEU  CA    C  55.435 
105   LEU  CG    C  23.696 
105   LEU  CD1   C  21.159 
105   LEU  CD2   C  19.907 
105   LEU  H     H   8.452 
105   LEU  HA    H   4.086 
105   LEU  HB2   H   1.838 
105   LEU  HB3   H   1.780 
105   LEU  HG    H   1.517 
105   LEU  HD1   H   0.798 
105   LEU  HD2   H   0.752 
105   LEU  N     N 121.762 
106   ARG  CA    C  53.157 
106   ARG  CB    C  29.252 
106   ARG  CG    C  26.004 
106   ARG  CD    C  39.213 
106   ARG  H     H   8.444 
106   ARG  HA    H   4.343 
106   ARG  HB2   H   1.822 
106   ARG  HB3   H   1.768 
106   ARG  HG2   H   1.642 
106   ARG  HG3   H   1.619 
106   ARG  HD2   H   2.947 
106   ARG  HD3   H   2.935 
106   ARG  N     N 118.210 
107   HIS  CA    C  56.237 
107   HIS  CB    C  27.033 
107   HIS  H     H   7.804 
107   HIS  HA    H   4.329 
107   HIS  HB3   H   3.311 
107   HIS  N     N 119.565 
108   VAL  CA    C  58.911 
108   VAL  CB    C  35.675 
108   VAL  CG1   C  
14.657 
108   VAL  CG2   C  
14.657 
108   VAL  H     H   7.761 
108   VAL  HA    H   3.611 
108   VAL  HB    H   1.959 
108   VAL  HG1   H   0.923 
108   VAL  HG2   H   0.923 
108   VAL  N     N 119.795 
109   MET  CB    C  31.008 
109   MET  CG    C  31.008 
109   MET  CE    C  19.047 
109   MET  H     H   8.141 
109   MET  HA    H   4.454 
109   MET  HB2   H   1.930 
109   MET  HB3   H   1.930 
109   MET  HG2   H   2.190 
109   MET  HG3   H   2.190 
109   MET  N     N 117.092 
110   THR  CA    C  62.951 
110   THR  CB    C  66.307 
110   THR  CG2   C  
18.745 
110   THR  H     H   8.025 
110   THR  HA    H   4.116 
110   THR  HB    H   4.243 
110   THR  HG2   H   1.184 
110   THR  N     N 115.739 
111   ASN  CA    C  52.420 
111   ASN  CB    C  38.398 
111   ASN  H     H   7.805 
111   ASN  HA    H   4.616 
111   ASN  HB2   H   2.632 
111   ASN  HB3   H   2.632 
111   ASN  N     N 122.761 
112   LEU  CA    C  51.724 
112   LEU  CB    C  39.540 
112   LEU  CG    C  23.252 
112   LEU  CD1   C  21.118 
112   LEU  CD2   C  19.846 
112   LEU  H     H   7.706 
112   LEU  HA    H   4.443 
112   LEU  HB2   H   1.839 
112   LEU  HB3   H   1.759 
112   LEU  HG    H   1.522 
112   LEU  HD1   H   0.801 
112   LEU  HD2   H   0.787 
112   LEU  N     N 119.226 
113   GLY  CA    C  42.816 
113   GLY  H     H   7.750 
113   GLY  HA2   H   4.198 
113   GLY  HA3   H   4.198 
113   GLY  N     N 107.622 
114   GLU  CA    C  56.502 
114   GLU  CB    C  26.600 
114   GLU  CG    C  33.342 
114   GLU  H     H   7.686 
114   GLU  HA    H   4.095 
114   GLU  HB2   H   2.070 
114   GLU  HB3   H   2.010 
114   GLU  HG2   H   2.361 
114   GLU  HG3   H   2.307 
114   GLU  N     N 121.196 
115   LYS  CA    C  52.791 
115   LYS  CB    C  29.252 
115   LYS  CG    C  21.917 
115   LYS  CD    C  26.248 
115   LYS  H     H   8.448 
115   LYS  HA    H   4.346 
115   LYS  HB2   H   1.758 
115   LYS  HB3   H   1.758 
115   LYS  HG2   H   1.353 
115   LYS  HG3   H   1.353 
115   LYS  HD2   H   1.615 
115   LYS  HD3   H   1.615 
115   LYS  HE3   H   2.932 
115   LYS  N     N 124.715 
116   LEU  CA    C  51.306 
116   LEU  CB    C  39.349 
116   LEU  CG    C  23.216 
116   LEU  CD1   C  21.082 
116   LEU  CD2   C  19.993 
116   LEU  H     H   7.972 
116   LEU  HA    H   4.446 
116   LEU  HB2   H   1.842 
116   LEU  HB3   H   1.758 
116   LEU  HG    H   1.520 
116   LEU  HD1   H   0.796 
116   LEU  HD2   H   0.758 
116   LEU  N     N 125.517 
117   THR  CA    C  57.848 
117   THR  CB    C  68.370 
117   THR  CG2   C  
18.854 
117   THR  H     H   9.085 
117   THR  HA    H   4.406 
117   THR  HB    H   4.745 
117   THR  HG2   H   1.282 
117   THR  N     N 115.354 
118   ASP  CA    C  55.203 
118   ASP  CB    C  37.636 
118   ASP  H     H   8.757 
118   ASP  HA    H   4.325 
118   ASP  HB2   H   2.640 
118   ASP  HB3   H   2.640 
118   ASP  N     N 121.684 
119   GLU  CA    C  57.059 
119   GLU  CB    C  25.551 
119   GLU  CG    C  33.405 
119   GLU  H     H   8.538 
119   GLU  HA    H   3.980 
119   GLU  HB2   H   2.070 
119   GLU  HB3   H   2.009 
119   GLU  HG2   H   2.361 
119   GLU  HG3   H   2.307 
119   GLU  N     N 119.819 
120   GLU  CA    C  56.502 
120   GLU  CB    C  25.842 
120   GLU  CG    C  33.204 
120   GLU  H     H   7.621 
120   GLU  HA    H   3.996 
120   GLU  HB2   H   2.059 
120   GLU  HB3   H   2.059 
120   GLU  HG2   H   2.369 
120   GLU  HG3   H   2.310 
120   GLU  N     N 121.226 
121   VAL  CA    C  64.170 
121   VAL  CB    C  28.630 
121   VAL  CG1   C  
20.996 
121   VAL  CG2   C  
20.996 
121   VAL  H     H   7.940 
121   VAL  HA    H   3.568 
121   VAL  HB    H   2.168 
121   VAL  HG1   H   0.914 
121   VAL  HG2   H   0.914 
121   VAL  N     N 121.814 
122   ASP  CA    C  54.786 
122   ASP  CB    C  37.422 
122   ASP  H     H   7.900 
122   ASP  HA    H   4.325 
122   ASP  HB2   H   2.719 
122   ASP  HB3   H   2.719 
122   ASP  N     N 120.391 
123   GLU  CA    C  56.178 
123   GLU  CB    C  26.455 
123   GLU  CG    C  33.296 
123   GLU  H     H   7.844 
123   GLU  HA    H   4.041 
123   GLU  HB2   H   2.062 
123   GLU  HB3   H   2.010 
123   GLU  HG2   H   2.346 
123   GLU  HG3   H   2.307 
123   GLU  N     N 120.238 
124   MET  CA    C  56.688 
124   MET  CB    C  29.523 
124   MET  CG    C  29.523 
124   MET  H     H   7.717 
124   MET  HA    H   4.005 
124   MET  HB2   H   2.197 
124   MET  HB3   H   2.197 
124   MET  HG2   H   2.465 
124   MET  HG3   H   2.465 
124   MET  N     N 120.048 
125   ILE  CA    C  61.137 
125   ILE  CB    C  33.459 
125   ILE  CG1   C  25.206 
125   ILE  CG2   C  13.479 
125   ILE  CD1   C   7.941 
125   ILE  H     H   7.819 
125   ILE  HA    H   3.474 
125   ILE  HB    H   2.094 
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125   ILE  HG12  H   1.259 
125   ILE  HG13  H   1.259 
125   ILE  HG2   H   0.688 
125   ILE  HD1   H   0.678 
125   ILE  N     N 119.153 
126   ARG  CA    C  55.853 
126   ARG  CB    C  29.902 
126   ARG  CG    C  25.896 
126   ARG  CD    C  39.213 
126   ARG  H     H   8.045 
126   ARG  HA    H   4.003 
126   ARG  HB2   H   1.819 
126   ARG  HB3   H   1.765 
126   ARG  HG2   H   1.641 
126   ARG  HG3   H   1.620 
126   ARG  HD2   H   2.948 
126   ARG  HD3   H   2.936 
126   ARG  N     N 118.995 
127   GLU  CA    C  55.714 
127   GLU  CB    C  26.564 
127   GLU  CG    C  33.187 
127   GLU  H     H   7.807 
127   GLU  HA    H   3.978 
127   GLU  HB2   H   2.062 
127   GLU  HB3   H   2.010 
127   GLU  HG2   H   2.355 
127   GLU  HG3   H   2.307 
127   GLU  N     N 116.921 
128   ALA  CA    C  49.265 
128   ALA  CB    C  16.097 
128   ALA  H     H   7.188 
128   ALA  HA    H   4.257 
128   ALA  HB    H   1.361 
128   ALA  N     N 119.386 
129   ASP  CA    C  49.543 
129   ASP  CB    C  36.452 
129   ASP  H     H   7.721 
129   ASP  HA    H   4.513 
129   ASP  HB2   H   2.332 
129   ASP  HB3   H   2.332 
129   ASP  N     N 117.657 
130   ILE  CA    C  60.632 
130   ILE  CB    C  35.636 
130   ILE  CG1   C  25.118 
130   ILE  CG2   C  14.492 
130   ILE  CD1   C   9.612 
130   ILE  H     H   8.197 
130   ILE  HA    H   3.868 
130   ILE  HB    H   1.958 
130   ILE  HG12  H   1.285 
130   ILE  HG13  H   1.285 
130   ILE  HG2   H   0.895 
130   ILE  HD1   H   0.845 
130   ILE  N     N 128.492 
131   ASP  CA    C  51.121 
131   ASP  CB    C  38.563 
131   ASP  H     H   8.167 
131   ASP  HA    H   4.582 
131   ASP  HB2   H   2.624 
131   ASP  HB3   H   2.624 
131   ASP  N     N 117.245 
132   GLY  CA    C  44.672 
132   GLY  H     H   7.440 
132   GLY  HA2   H   3.801 
132   GLY  HA3   H   3.801 
132   GLY  N     N 109.147 
133   ASP  CA    C  50.981 
133   ASP  H     H   8.196 
133   ASP  HA    H   4.575 
133   ASP  HB2   H   2.636 
133   ASP  HB3   H   2.636 
133   ASP  N     N 121.555 
134   GLY  CA    C  42.909 
134   GLY  H     H  10.217 
134   GLY  HA2   H   4.006 
134   GLY  HA3   H   4.006 
134   GLY  N     N 113.583 
135   GLN  CA    C  50.425 
135   GLN  CB    C  29.930 
135   GLN  CG    C  30.473 
135   GLN  H     H   7.819 
135   GLN  HA    H   4.838 
135   GLN  HB2   H   1.661 
135   GLN  HB3   H   1.661 
135   GLN  HG2   H   1.906 
135   GLN  HG3   H   1.906 
135   GLN  N     N 116.063 
136   VAL  CA    C  59.008 
136   VAL  CB    C  30.775 
136   VAL  CG1   C  
19.122 
136   VAL  H     H   9.001 
136   VAL  HA    H   5.167 
136   VAL  HB    H   2.254 
136   VAL  HG1   H   1.226 
136   VAL  HG2   H   0.888 
136   VAL  N     N 126.088 
137   ASN  CA    C  48.383 
137   ASN  H     H   9.370 
137   ASN  HA    H   5.137 
137   ASN  HB2   H   2.751 
137   ASN  HB3   H   2.479 
137   ASN  N     N 129.697 
138   TYR  CA    C  59.965 
138   TYR  CB    C  34.840 
138   TYR  H     H   8.313 
138   TYR  HA    H   3.373 
138   TYR  HB2   H   2.327 
138   TYR  HB3   H   2.327 
138   TYR  N     N 119.170 
139   GLU  CA    C  56.707 
139   GLU  CB    C  26.203 
139   GLU  CG    C  33.545 
139   GLU  H     H   8.012 
139   GLU  HA    H   3.997 
139   GLU  HB2   H   2.063 
139   GLU  HB3   H   2.009 
139   GLU  HG2   H   2.357 
139   GLU  HG3   H   2.312 
139   GLU  N     N 119.324 
140   GLU  CA    C  55.760 
140   GLU  CB    C  26.455 
140   GLU  CG    C  33.296 
140   GLU  H     H   8.624 
140   GLU  HA    H   4.069 
140   GLU  HB2   H   2.069 
140   GLU  HB3   H   2.015 
140   GLU  HG2   H   2.354 
140   GLU  HG3   H   2.320 
140   GLU  N     N 120.448 
141   PHE  CA    C  58.961 
141   PHE  CB    C  37.262 
141   PHE  H     H   8.781 
141   PHE  HA    H   3.917 
141   PHE  N     N 125.424 
142   VAL  CA    C  64.297 
142   VAL  CB    C  28.735 
142   VAL  CG1   C  
20.048 
142   VAL  CG2   C  
20.048 
142   VAL  H     H   8.436 
142   VAL  HA    H   3.068 
142   VAL  HB    H   1.806 
142   VAL  HG1   H   0.446 
142   VAL  HG2   H   0.446 
142   VAL  N     N 120.162 
143   GLN  CA    C  56.131 
143   GLN  CB    C  25.436 
143   GLN  CG    C  31.282 
143   GLN  H     H   7.286 
143   GLN  HA    H   3.792 
143   GLN  HB2   H   2.086 
143   GLN  HB3   H   2.086 
143   GLN  HG2   H   2.366 
143   GLN  HG3   H   2.366 
143   GLN  N     N 118.871 
144   MET  CA    C  58.850 
144   MET  CB    C  36.968 
144   MET  CG    C  37.402 
144   MET  H     H   7.775 
144   MET  HA    H   3.923 
144   MET  HB2   H   2.003 
144   MET  HB3   H   2.004 
144   MET  HG2   H   2.319 
144   MET  HG3   H   2.319 
144   MET  N     N 119.756 
145   MET  CA    C  52.559 
145   MET  CB    C  29.170 
145   MET  CG    C  29.713 
145   MET  CE    C  15.122 
145   MET  H     H   7.705 
145   MET  HA    H   4.246 
145   MET  HB2   H   1.620 
145   MET  HB3   H   1.620 
145   MET  HG2   H   1.749 
145   MET  HG3   H   1.749 
145   MET  HE    H   1.924 
145   MET  N     N 115.739 
147   ALA  CA    C  50.100 
147   ALA  CB    C  16.269 
147   ALA  H     H   7.598 
147   ALA  HA    H   4.263 
147   ALA  HB    H   1.355 
147   ALA  N     N 127.202 
148   LYS  CA    C  54.739 
148   LYS  CB    C  26.274 
148   LYS  CG    C  21.815 
148   LYS  CD    C  30.787 
148   LYS  CE    C  39.649 
148   LYS  H     H   7.576 
148   LYS  HA    H   4.072 
148   LYS  HB2   H   1.621 
148   LYS  HB3   H   1.621 
148   LYS  HG2   H   1.350 
148   LYS  HG3   H   1.350 
148   LYS  HD2   H   1.767 
148   LYS  HD3   H   1.767 
148   LYS  HE2   H   2.927 
148   LYS  HE3   H   2.927 
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